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v. Abstract 
Objective: There is limited data describing acute kidney injury (AKI) in HIV-infected 
adult patients in resource-limited settings where increasingly, tenofovir (TDF), which 
is potentially nephrotoxic, is prescribed. We describe risk factors for, and prognosis of 
AKI in HIV-infected individuals receiving and naïve to TDF.  
Methods: This was a prospective case cohort study of hospitalized HIV-infected 
adults with AKI (as defined by the 2012 KDIGO Clinical Practice Guideline for AKI) 
stratified by TDF exposure. Adults (≥18 years) were recruited: clinical and 
biochemical data was collected at admission; their renal recovery, discharge or 
mortality was ascertained as an in-patient and, subsequently, to a scheduled 3-month 
follow-up.  
Results: Amongst this predominantly female (61%), almost exclusively black African 
cohort of 175 patients with AKI, 93 (53%) were TDF exposed; median age was 41 
years (IQR 35-50). Median CD4 count and VL and creatinine at baseline was 116 
cells/mm3 and 110159 copies/ml, respectively. A greater proportion of the TDF group 
had severe AKI on admission (61% v 43% p=0.014); however, both groups had 
similar rates of newly diagnosed tuberculosis (TB) (52%) and NSAID (32%) use. 
Intravenous fluid was the therapeutic mainstay; only 7 were dialyzed. Discharge 
median serum creatinine (SCr) was higher in the TDF group (p=0.032) and fewer in 
the TDF group recovered renal function after 3-months (p=0.043). 3-month mortality 
was 27% in both groups but 55% of deaths occurred in hospital. Those that died had a 
higher SCr and more severe AKI than survivors; TB was diagnosed in 33 (70%) of 
those who died. 
Conclusions: AKI was more severe and renal recovery slower in the TDF group; co-
morbidities, risk factors and prognosis were similar regardless of TDF exposure. 
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Because TB is linked to higher mortality, TB co-infection in HIV-infected patients 
with AKI warrants more intensive monitoring. In all those with poor renal recovery, 
our data suggests that a lower threshold for dialysis is needed. 
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Chapter 1: Protocol and Extended review of the literature 
Background 
1.1 Introduction 
Acute kidney injury (AKI) is a major cause of mortality and morbidity in HIV 
infected individuals and has a multifactorial aetiology.[1-3] HIV is directly 
nephrotoxic and viral infection of renal glomerular and tubular cells can cause an HIV 
associated nephropathy, but the role of HIV in renal disease remains complex and 
includes: the nephrotoxic effects of HIV; the direct effects or sequelae of 
opportunistic infections on renal function; and the nephrotoxic effects of antiretroviral 
drugs.[4-6] Tenofovir (TDF), with emtricitibine and efavirenz is dispensed as part of 
the fixed dose combination (FDC) antiretroviral therapy (ART) tablet and, since April 
2010, has been the mainstay of the first line ART regimen in South Africa.[7-9] TDF 
has been cited as a cause for AKI and it is postulated host genetic polymorphisms 
play a role in increasing the risk of developing TDF-related nephrotoxicity in certain 
individuals.[10, 11] There is a paucity of data describing AKI in HIV-infected 
individuals both in those receiving TDF-based ART and in ART-naïve individuals. 
With greater TDF use in the health sector this prospective case-cohort study, 
comparing HIV positive patients with AKI who are TDF exposed to those TDF un-
exposed, reports the presentation, severity and risk factors for AKI in TDF exposed 
HIV positive patients, and assesses short – term survival and response to treatment. 
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1.2 HIV 
1.2.1 HIV – a South African Health Issue 
HIV is a major in health issue in South Africa with significant cost implications – 
particularly with regard to in-patient hospital care. 18% of adults in South Africa are 
HIV seropositive and the 6.2 million people infected in South Africa accounts for 
17% of all HIV positive people worldwide.[12, 13] Only since 2004 has ART been 
available and in mid – 2015 3.1 million South Africans were on ART. The number of 
AIDS – related deaths in South Africa for 2015 was 162445, comprising 30.5% of the 
total deaths for 2015.[14, 15] A multi – country analysis of treatment costs for ART 
provision estimated the cost of ART per patient year to be $682 (United States 
Dollars [USD]), whilst a South African study from a Gauteng hospital of the cost of 
in-patient care for HIV positive patients estimated an average cost of  $1783 (USD) 
per hospital admission.[16, 17]   
1.2.2 HIV Lifecycle 
Following acute infection with HIV  - an RNA virus – viral entry into the CD4 cell 
occurs via gp120 and gp41 viral membrane proteins binding to CD4 cell membrane 
receptors and an adjacent chemokine co-receptor (either CC Chemokine receptor 
CCR5 or CXR4). Fusion between the virus envelope and CD4 cell membrane 
facilitates viral entry and once within the cell the enzyme reverse transcriptase un-
coats the viral core. Viral double stranded DNA is produced and is integrated into 
host DNA by the enzyme integrase. Transcription of mRNA, translation and 
subsequent production of viral proteins and viral RNA follows. These products are 
assembled and the virus matures before being released from the cell as a fully 
matured new HIV copy.[18, 19] HIV has a high rate of viral replication and 
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inaccuracies during reverse transcription may result in mutations in newly produced 
viral copies. Consequently, genetic diversity exists both within and between 
individuals.[20]  
1.3. Renal Disease 
Renal disease is a heterogeneous group of disorders and newer classifications 
consider disease duration an important differentiating factor.[21]  
1.3.1 Definitions of Renal Disease 
1.3.1.1 Acute kidney injury 
The traditional definition of acute renal failure is: “a rapid fall in the rate of 
glomerular filtration, which manifests clinically as an abrupt and sustained increase in 
the serum levels of urea and creatinine with an associated disruption of salt and water 
homeostasis.”[22] This definition has limitations in clinical practice, as the terms 
“rapid”, “abrupt” and “sustained” are unclear. Several alternative consensus 
definitions of acute renal failure have been considered over the last decade.[23] In 
2000, the RIFLE definition was proposed by the Acute Dialysis Quality Initiative and 
refers to 5 stages of acute renal failure – risk of renal dysfunction, injury to the 
kidney, failure of kidney function, loss of kidney function and end stage renal disease. 
In 2005 the Acute Kidney Injury Network (AKIN) proposed the newer term “acute 
kidney injury”.[22] Thereafter, in 2012 the Kidney Disease Improving Clinical 
Outcomes (KDIGO) re-defined AKI as any one of three entities: an increase in serum 
creatinine by more than 26.4umol/l in 48 hours; an increase in serum creatinine by 
more than 1.5 times the baseline which is known or presumed to have occurred within 
the last seven days or urine output less than 0.5ml/kg/hr for the last 6 hours.[24] 
Furthermore, a staging system of severity dividing acute kidney injury into 3 stages,  
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depending on degree of creatinine elevation from baseline or decline in urine output, 
was added.[24]  
1.3.1.2 Chronic kidney disease 
KDIGO define chronic kidney disease (CKD) by abnormalities of kidney structure or 
function, which is present for more than 3 months, with implications for health. 
Abnormalities of kidney structure and function are defined by: an estimated 
glomerular filtration rate (eGFR) of less than 60 or by one of the following markers of 
kidney damage: albuminuria > 30mg/24 hours or albumin creatinine ratio > 30mg/g, 
urine sediment abnormalities, electrolyte and other abnormalities due to tubular 
disorders, abnormalities detected by imaging or renal biopsy or a history of kidney 
transplantation.[25] The glomerular filtration rate is then used to classify the stage of 
CKD into one of five stages.[25] 
1.3.2 Acute kidney injury in HIV 
The risk of AKI in all HIV positive individuals, both ART naive and those on ART, is 
increased. Although HIV positive individuals share similar risk factors and causes for 
AKI to those who are uninfected, certain factors are unique to HIV-infected 
individuals that predispose to and cause AKI.[26, 27] 
1.3.2.1 Epidemiology of AKI in HIV 
Many studies have highlighted the increased incidence of AKI in HIV infected 
individuals. In a cohort study of 754 ambulatory HIV infected patients from North 
Carolina the incidence of AKI was 5.9 per 100 person years.[28] Whilst, in a 
retrospective cohort of 2274 HIV infected outpatients from London 2.7 episodes of 
AKI occurred per 100 person – years.[29] A New York study that compared adult 
hospitalized patients with AKI during the year 1995 (pre-ART era) and the year 2003 
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(post –ART era), reported significantly more AKI in HIV infected patients compared 
to HIV negative patients in both the pre- and post ART era: 1995 (2.9 verses 1%) and 
2003 (6 verses 2.7%). Furthermore, the odds ratios for the occurrence of AKI in HIV 
– infected patients were 4.62 (pre-ART) and 2.82 (post ART).[1] Two retrospective 
cohorts reported similarly high rates of AKI amongst hospitalized HIV positive 
patients. One in six of 17325 patients from a U.S. registry of hospitalized HIV- 
infected patients developed AKI and 18% of 489 HIV – infected hospitalized patients 
in Lisbon were diagnosed with AKI.[30, 31] A 2012 systematic review and meta-
analysis calculated the relative risk of kidney disease in people living with HIV of 
3.87 compared to HIV – uninfected people.[32] South African data detailing the 
incidence of AKI in HIV positive patients is limited.[27, 33] In a Johannesburg 
retrospective cohort of 684 hospitalized adult patients with AKI 14.8% were HIV 
positive.[34] In this cohort HIV positive patients presented with more severe AKI: 
72% of HIV positive patients were classified in the Failure category of the RIFLE 
classification compared to 44% of HIV negative patients.[34] In a study from rural 
Kwa-Zulu Natal of 2189 patients initiating ART, 14.4% of patients had moderate to 
severe renal impairment (an eGFR of less than 60).[35]  
1.3.2.2 HIV associated risk factors and AKI 
Traditional risk factors for AKI in seronegative patients, also apply to HIV 
seropositive individuals, include: increasing age (age greater than 65), black race, 
hypertension, diabetes, chronic kidney disease, exposure to radio-contrast, injection 
drug use, viral hepatitis co – infection and cirrhosis. [1, 28-32, 36, 37] In patients with 
HIV, hepatitis C co-infection is associated with an increase risk of AKI but no 
association with hepatitis B co-infection is noted.[29, 36, 38, 39] Risk factors for AKI 
specific to HIV seropositive individuals comprise: male sex, immunosuppression - 
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evidenced by CD4 counts less than 200, presence of an AIDS defining condition, 
advanced HIV disease - HIV RNA level greater than 10000copies/mL, long term 
ART use, use of prophylactic cotrimoxazole, admission to an intensive care unit 
during hospital stay and pre-existing renal or liver disease.[28-32, 36-41] In South 
Africa: male sex, age greater than 40 and a CD4 count of less than 100 are associated 
with increased risk for AKI in ambulatory patients initiating ART, while in 
hospitalized HIV positive patients with AKI, active tuberculosis (TB) was reported as 
a risk factor for AKI and 98% of patients were black - although this finding may be as 
a result of the epidemiological characteristics and spread of HIV unique to South 
Africa.[34, 35] Moreover, exposures to herbal or traditional medications are important 
risk factors for AKI in South African HIV seropositive patients.[26, 27]  
1.3.2.3 Aetiology of AKI in HIV 
The aetiology of AKI in the HIV positive patient is diverse. Mechanisms of AKI can 
be divided into 3 categories: pre – renal AKI, intrinsic renal injury or post renal 
obstruction.[2, 3, 6, 28]  
1.  Pre-renal AKI from renal hypo perfusion due to intravascular fluid depletion 
occurs commonly in this setting.[6] Pre-renal AKI was present in 43% of ambulatory 
patients with AKI, in a North Carolina study, whilst the in a Lisbon hospital 
prevalence was 21.6%.[28, 30] Pre-renal AKI from renal hypo-perfusion may be 
multifactorial and aetiology includes: gastroenteritis, vomiting, septicemia (often 
from opportunistic infections), decompensated liver cirrhosis or cardiomyopathy.[2, 
3, 6, 28, 29] In South Africa, gastroenteritis and dehydration are often cited as causes 
pre-renal AKI whilst at a Johannesburg hospital 20% of hospitalized HIV positive 
patients with AKI result from volume depletion and haemodynamic instability.[27, 
34, 42]  
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2.  Intrinsic renal injury may lead to AKI in HIV-infected individuals and can be 
categorized as: acute tubular necrosis (ATN), acute interstitial nephritis (AIN), 
glomerular disease and crystal nephropathies.[2, 6]  
a) AKI from ATN occurred in 41% of ambulatory HIV-infected patients in North 
Carolina, whilst, in a Cape Town review 58% of HIV positive patients requiring renal 
replacement therapy were clinically diagnosed with ATN. ATN may result from 
numerous scenarios.[26, 28]  
i) Sepsis causes ATN due to direct tubular toxicity or via hypotension leading to renal 
ischemia and is the commonest cause of AKI in the HIV positive population –
occurring in 59% of HIV positive patients in a Lisbon hospital.[2, 6, 30, 43] A similar 
experience is noted in the South African literature at a Johannesburg hospital where 
62% of HIV seropositive patients with AKI were sepsis related.[26, 27, 34, 42] 
ii) ATN occurs from co – administration of nephrotoxic drugs and in the Lisbon 
cohort was implicated in 37.5% HIV positive patients with AKI.[30, 38] Nephrotoxic 
drugs include: aminoglycosides, amphotericin b, pentamidine, foscarnet, cidofovir - 
agents frequently used to treat opportunistic infections.[2, 6, 28, 38] Furthermore, 
non-steroidal anti-inflammatory drugs (NSAID) and lithium have been linked to the 
development of ATN.[6, 28] The antiretrovirals (ARVs) TDF (a nucleoside reverse 
transcriptase inhibitor or NRTI) and ritonavir (a protease inhibitor or PI) cause 
ATN.[5, 44] In South Africa this is further complicated by traditional or herbal 
medication use and may be derived from nephrotoxic plants such as Impila (Callilepis 
laureola) which may used by traditional healers, to treat AIDS related illness.[26, 27, 
42, 45]  
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iii) Other causes of ATN include: contrast nephropathy from radiological contrast 
media and rhabdomyolysis due to ARVs (zidovudine or didanosine), statin use or 
HIV-related myopathy.[2, 3, 6, 28, 30, 44]  
b) Acute Interstitial nephritis (AIN) - inflammation of the interstitium surrounding the 
tubules - causes AKI in HIV infected individuals.[6] AIN induced AKI, in North 
Carolina, occurred in 5% of ambulatory HIV positive patients with AKI and may be 
due to an allergic idiosyncratic drug reaction from opportunistic infections or the 
drugs used to treat them.[2, 6, 28] Beta – lactam antibiotics, rifampicin, quinolones, 
sulfamethaxazole/trimethoprim can all cause AIN whilst other drugs implicated 
include: histamine – 2 –receptor blockers and NSAIDs.[2, 3, 6, 44] Opportunistic 
infections causing AIN include: TB, cytomegalovirus and candidiasis.[2] 
Histologically, renal TB appears as diffuse interstitial disease but may be difficult to 
distinguish from AIN caused by anti – TB drugs.[26] Furthermore, AIN has been 
described as part of the immune reconstitution inflammatory syndrome (IRIS), 
whereby, restoration of the immune system following ART may result in interstitial 
inflammation to both non – infectious and infectious agents in the kidney, such as TB, 
and can be confirmed by granulomatous nephritis on renal biopsy.[3] 
c) Glomerular disease contributes to AKI in HIV infected individuals.[2, 3, 40, 44] In 
South Africa, thrombotic microangiopathies - thrombotic thrombocytopenic purpura 
and hemolytic uremic syndrome - cause AKI in the HIV positive population.[2, 3, 27, 
40, 44] A Paris retrospective cohort of 92 HIV positive patients with AKI – 60 of 
whom had renal biopsies – described 32 cases of hemolytic uremic syndrome with 26 
of these biopsy-proven.[40] Direct infection of renal cells by the HIV virus may result 
in an HIV associated nephropathy (HIVAN) with rapid progression to end stage renal 
disease – particularly in black patients.[44] In a Johannesburg study HIVAN was 
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present in 27% of renal biopsies performed over a 2-year period whilst the immune 
mediated glomerulonephritide, HIV immune complex kidney (HIVICK), was found 
in 21% of the biopsies.[4] Other glomerulonephritides in the HIV population that may 
present with AKI include: immune mediated glomerulonephritides - membranous 
glomerulopathy (which can be caused by hepatitis B or C virus) or post-infectious 
glomerulonephritides; IgA nephritis; mixed sclerotic/inflammatory disease and lupus-
like disease.[2, 4, 44]  
d) A crystal nephropathy or post-renal injury can be caused by nephrolithiasis as a 
result of tumour-lysis syndrome from lymphoma or drugs used to treat opportunistic 
infections such as: acyclovir, the protease inhibitor atazanavir as well as the rarely 
utilized ARV indinavir.[2, 3, 6, 28, 44]  
3.  Obstructive uropathy may result from bladder dysfunction syndromes – 
neuropathic bladder - and external obstruction from cervical carcinoma or 
retroperitoneal lymph nodes in patients with lymphoma. Moreover, therapeutic 
radiotherapy may contribute, due to resulting fibrosis and bilateral ureteral 
encasement.[2, 3, 6, 28]  
Despite the diverse range of disease processes causing AKI the leading cause in the 
HIV-infected adults remains pre-renal AKI or ATN with sepsis the predominant 
underlying cause of both entities.[26-28, 30, 34, 40, 42] 
1.3.2.4 Mortality of AKI in HIV 
HIV-infected patients admitted to hospital with AKI have a greater mortality rate than 
those without AKI. Mortality, in a cohort of HIV positive patients in Lisbon, admitted 
with AKI has been reported as 27.3% compared to 8% in those without AKI.[30] 
Even in the era of ART use, a New York study reported a six-fold increase in 
mortality in HIV positive patients with AKI compared to those without AKI.[1] HIV 
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seropositive hospitalized patients with AKI who subsequently recovered to normal 
renal function still had a 20% higher risk of mortality compared to those who never 
developed AKI, furthermore, a more severe stage of AKI (measured by the AKIN 
criteria) was associated with a greater risk of mortality.[31] South African data is 
limited but a mortality rate of 42% was reported in a Johannesburg cohort in HIV 
positive patients with AKI and factors predicting mortality included: hyponatremia, 
acidosis, hyperphosphatemia and the presence of anaemia.[34]  
1.3.2.5 Measures of Severity:  Glomerular Filtration Rate  
Current estimates of glomerular filtration rate (eGFR) include: the Cockroft - Gault 
equation (CG), Modification of Diet in Renal Disease (MDRD) and Chronic Kidney 
Disease Epidemiological Collaboration (CKD – EPI). No formula has been validated 
for use in HIV positive patients.[46, 47] Each of these formulas have limitations and 
concerns exist over their use in HIV positive patients who may have reduced muscle 
mass and an altered surface area to volume ratio that may influence their reliability 
and result in underestimation of eGFR.[47-49] Current recommendations support the 
use of CKD – EPI for the calculation of eGFR in HIV positive individuals.[47, 49]  
1.4. Tenofovir 
1.4.1 TDF use in South Africa 
In October 2001, TDF was approved by the Food and Drug Administration (FDA) as 
the first NRTI for the treatment of HIV.[50] Following recommendations from the 
World Health Organization (WHO), in 2010 the South African Department of Health 
recommended the use of TDF as a first line ARV – ahead of stavudine and zidovudine 
due to its favorable side effect profile.[7, 51] The latest South African Department of 
Health guideline recommends the once daily FDC antiretroviral regime – consisting 
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of: TDF, emtricibine and efavirenz - as first line therapy for HIV positive patients to 
be used in both those initiated onto ART and to those already on 1st line ART.[8, 52] 
The CD4 count threshold for the initiation of ART was raised from 200 cells/mm3 to 
350 cells/mm3 in 2013 and again in 2015 it was increased to 500 cells/mm3.[8, 9] 
Consequently, the number of patients being exposed to TDF has increased since 2010.  
1.4.2 Pharmacology 
TDF is a nucleotide analogue HIV-1 and HIV-2 reverse transcriptase inhibitor and is 
the only nucleotide reverse transcriptase inhibitor available.[50]   
It is initially administered as tenofovir disoproxil fumarate – its ester – derived 
prodrug. Following diester hydrolysis in the intestinal lumen and plasma and 
subsequent phosphorylation by cellular enzymes it is converted to the active form - 
tenofovir diphosphate.[50, 53] Tenofovir diphosphate, the nucleotide base analogue, 
is incorporated into HIV DNA by the reverse transcriptase enzyme during viral DNA 
formation. These nucleotides cannot form the necessary chemical bonds to other 
DNA base pairs and prevent addition of functional nucleotides to the replicating 
DNA. DNA elongation is halted resulting in the inability to produce new HIV 
virus.[18, 50, 53] The oral bioavailability of TDF is 25% and despite initial 
manufacturer recommendations, currently, it is recommended TDF be taken once 
daily irrespective of related food consumption.[50, 53] Elimination of TDF occurs via 
glomerular filtration and tubular secretion – over 72 hours 70 – 80% of unchanged 
drug is found in the urine. TDF has an intracellular half-life of 10 – 50 hours and 
levels decline in a biphasic manner with a terminal elimination half-life of 17 
hours.[50, 53]  
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1.4.3 Tenofovir and Nephrotoxicity 
1.4.3.1 History of the association between Tenofovir and nephrotoxicity  
TDF is structurally similar to other acylic nucleotide analogues that cause renal 
dysfunction and hypophosphatemia - adefovir and cidofovir.[54, 55] Despite this 
similarity, two initial U.S. based phase I/II randomized double blind placebo-
controlled clinical trials did not demonstrate nephrotoxicity with TDF use after 28 
days or 48 weeks.[56-58] However, as TDF was introduced into clinical practice, case 
reports and series emerged from the USA and Europe reporting declining renal 
function with TDF use.[59-68] Subsequently, TDF associated nephrotoxicity was 
described in various observational cohort studies conducted mostly in the developing 
world - USA, Europe and Australasia.[41, 54, 69-75] The most significant cohort, 
Nelson et al, included 10343 patients enrolled in the TDF expanded access program 
over a 4 year period from the USA, Europe and Australia - all of whom had failed 
previous ART and were now switched to TDF. Post-marketing safety data, reporting 
serious adverse events associated with TDF use submitted to Gilead- the 
pharmaceutical company developing TDF- over a 6-month period was also 
examined.[72] A decline in creatinine clearance of more than 20% was found in 16% 
of the TDF exposed group verses 11% of the TDF unexposed group in an American 
prospective cohort comparing renal function in 593 HIV positive TDF exposed 
outpatients to 521 TDF – unexposed patients.[76] In 2010, the association of TDF 
with declining renal function was described in a prospective Senegalese cohort of 40 
patients starting a TDF based ART regimen compared to 388 initiating Non-TDF 
based ART.[71] South African data supporting the association of TDF and 
nephrotoxicity is described in two cohort studies. The first, Brennan et al, comprised 
890 HIV positive ambulatory patients from Johannesburg, the majority of whom were 
	 13	
black and female, that were either newly initiated or switched to TDF from a pre-
existing ART regimen and the second, Kamkuemah et al, included 1092 ambulatory 
HIV positive ART naïve patients initiated on TDF – based ART in a primary 
healthcare Clinic in Cape Town.[74, 77]  In 2010 a systemic review and meta-analysis 
by Cooper et al: 11 studies confirmed significant decline in renal function associated 
with TDF use with a mean difference in CG eGFR of 3.92mL/min; [95% confidence 
interval, 2.13 to 5.70mL/min]. Six more studies that used the MDRD formula noted a 
difference in kidney function of 2.56mL/min; [95% confidence interval, -0.57 to 
5.69].[78] It is postulated that exclusion of patients with underlying risk factors for 
renal disease from early clinical trials led to publication bias and may explain the 
discrepancy noted in later findings in clinical practice.[78, 79] 
1.4.3.2 Incidence and Prevalence  
TDF related nephrotoxicity is considered uncommon and its incidence and prevalence 
is described in numerous studies.[41, 69, 70, 72, 74-78, 80] In Nelson et al, 2.2% of 
the cohort had a grade 1 rise in creatinine of 44umol/L from baseline whilst 0.6% of 
patients had a rise of serum creatinine to greater than 177umol/L from baseline.[72] A 
U.S. retrospective cohort studied ART naïve patients commenced on ARVs: 964 were 
initiated onto TDF containing regimens compared to 683 initiated onto TDF sparing 
regimens. In the TDF exposed group 4.8% of patients had a 50% or more decline in 
eGFR from baseline but the serum creatinine did not rise to greater than 
177umol/L.[80] A recent Madrid based prospective cohort assessed both ART 
experienced and naïve patients and observed AKI in 10% of patients exposed to TDF 
with a calculated incidence of 5.9 cases per 100 patient years.[41] Other cohorts from 
the Western world calculated a prevalence of 0.3% of AKI in the TDF group whilst 
the incidence of AKI in TDF was reported as: 1.6 per 100 person years and 0.71 per 
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100 person years with an incidence ratio of 1.98 - but greater grades of creatinine 
elevation were associated with a lesser incidence ratio of 1.27.[70, 75, 76] In South 
Africa, Brennan et al report 2.4% of TDF exposed patients experienced 
nephrotoxicity (any decline in kidney function from baseline) at 48 month follow up 
and from Kamkuemah et al the incidence of decline of renal function of more than 
10ml/min/1.73m2 at 12 months after TDF initiation was 96 per 100 person – 
years.[74, 77] Cooper et al, calculated the risk of developing AKI with TDF use as 
0.7%.[78]  
1.4.3.3 Duration of Tenofovir exposure to onset of declining renal function 
The onset of declining renal function associated with TDF occurs several months 
following TDF initiation. A number of cohorts have described nephrotoxicity at a 
mean and median time of 6 – 9 months following TDF initiation.[41, 57, 69, 70, 72] 
In contrast, cohorts from South Africa report a shorter time to nephrotoxicity: 
Brennan et el report a median time of 3.6 months to the development of 
nephrotoxicity and Kamkuemah et al had the greatest incidence of a decline in renal 
function during the first 2 months on TDF based ART.[74, 77] 
1.4.3.4 Pathophysiology  
During renal elimination, TDF crosses cells of the proximal tubule to be excreted via 
the urine. Initially, TDF enters the proximal tubule cell via the basolateral membrane 
through organic anion transporters (OAT), OAT 1 and OAT 3, and crosses the cell to 
exit the cell via the apical membrane through the transmembrane multidrug resistance 
protein (MRP) transporter 4. (The apical surface also has a second transporter, MRP 2 
– for which implications on TDF transport across the apical membrane is 
incompletely understood.)[5, 11, 79, 81, 82] The imbalance between the influx and 
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efflux of TDF into cells results in intracellular TDF accumulation which inhibits 
mitochondrial DNA (mtDNA) replication through inhibition of the mtDNA-
producing enzyme DNA polymerase γ.[5, 83] This effect is toxic to the mitochondria 
of these cells and mitochondrial dysfunction ensues resulting in proximal tubule 
dysfunction.[5, 11, 67, 79, 81, 84]  
1.4.3.5 Clinical manifestations  
The clinical presentation of proximal tubulopathy is characterized by the following: 
Fanconi syndrome, ATN with AKI and TDF related bone disease. [5, 11, 67, 79, 81, 
84] The proximal tubule has two notable functions: the reabsorption of fluid and 
nutrients filtered by the glomerulus and production of 1.25-dihydroxy-vitamin D. In 
the proximal tubule, 60 – 70% of the water and sodium chloride from glomerular 
ultrafiltrate and important nutrients such as: glucose, potassium, amino acids, 
bicarbonate and phosphate are reabsorbed and 25–hydroxy–vitamin D is converted to 
its active form 1.25-dihydroxy-vitamin D.[85] Proximal tubular toxicity from TDF 
results in loss of these functions. Reabsorption fails and increased quantities of 
important nutrients and anions are lost in the urine. A complete or partial Fanconi 
syndrome may occur, characterized by: tubular proteinuria, aminoaciduria, glycosuria 
in the presence of normoglycemia, phosphaturia leading to hypophosphatemia, 
hypokalemia due to potassium losses and bicarbonaturia, which leads to a renal 
tubular acidosis.[11, 79, 80, 86] This can be further categorised as proximal tubular 
dysfunction with preserved or reduced renal function.[79] As proximal tubular 
dysfunction progresses ATN with AKI may occur – evident by an increasing serum 
creatinine.[11, 79, 81, 87] Bone disease, reduction in bone density and subsequent 
osteomalacia, associated with TDF is due to excess urinary phosphate losses and 
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decreased active vitamin D production resulting in reduced calcium absorption.[11, 
67, 79]  
1.4.3.6 Biochemical markers 
Biochemical markers of proximal tubulopathy include a rising serum creatinine, 
glycosuria on urine dipsticks and an elevated spot urine protein: creatinine ratio. A 
urine dipsticks test cannot be used to detect urine protein losses as mainly albuminuria 
is detected and not tubular proteins.[67] Other tests include serum hypophosphatemia, 
serum hypokalemia and serum ph.[79, 84] Subclinical renal tubular toxicity may be 
diagnosed through the detection of smaller sized tubular proteins lost in the urine 
during the early stages of proximal tubular dysfunction: β 2 – microglobulin, retinol 
binding protein or N- Acetyl – β – D – glucosaminidase.[67, 84, 88]  
1.4.3.7 Histological features  
Studies have described histological features of patients with TDF related 
nephrotoxicity that support TDF is toxic to mitochondria of the proximal tubule.[44, 
67, 83, 87, 89] Large eosinophilic intracytoplasmic inclusions representing giant 
mitochondria are noted within the proximal tubule epithelium and electron 
microscopy of the proximal tubule epithelium reveals dysmorphic mitochondria with 
variable size and shape and reduced in number.[67, 83, 87] Features in keeping with 
toxic ATN are noted on light microscopy.[87, 89] 
1.4.3.8 Risk Factors  
A number of studies have considered risk factors, with differing results, that 
predispose patients to TDF nephrotoxicity. Older patients and males are shown to be 
at a higher risk of nephrotoxicity with TDF use, as is white race. [70, 76, 78, 80, 82, 
90] Co – morbid diabetes, hypertension, cardiovascular disease and cirrhosis is 
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associated with an increase risk of TDF related nephrotoxicity.[54, 72, 80, 84, 90, 91] 
Patients who are underweight, with hepatitis B or C co-infection, or are admitted with 
sepsis or severe infections are predisposed to TDF associated nephrotoxicity.[61, 72, 
76, 90] Regarding HIV, patients with advanced HIV disease (baseline CD4 counts – 
less than 50 cells/mm3 – and higher baseline HIV viral load – more than 
20000copies/ml) have a greater risk of TDF associated AKI.[41, 54, 61, 70, 72, 74, 
76, 78, 84] Furthermore, patients who are ART naïve and initiated on TDF based 
regimens have less risk of AKI compared to those who are ART experienced and 
subsequently switched to a TDF containing regimen.[54, 74, 76, 78] The duration of 
TDF exposure is described by one study as a risk factor for AKI.[76] In patients with 
pre-existing renal disease - elevated baseline serum creatinine or reduced baseline 
eGFR – the risk of TDF associated nephrotoxicity is higher.[54, 69, 72, 74, 76, 78] 
Concomitant nephrotoxic drug use such as the non – steroidal anti-inflammatory 
diclofenac and concomitant use of the antibiotic sulfamethoxazole-trimethoprim is 
associated with a greater risk of AKI due to TDF.[41, 72, 84, 92] Concomitant PI use, 
as part of a TDF containing ART regimen – such as ritonavir - is noted to increase the 
risk of TDF related nephrotoxicity due to the inhibition of the MRP 2 transporter in 
the apical surface of the proximal tubule cell resulting in excess TDF accumulation 
within the cell.[41, 54, 61, 70, 80, 84, 90, 91]  
1.4.3.9 Genetic Predisposition  
Genetic polymorphisms in genes that code for the drug transporters of the apical 
membrane of the proximal tubule result in transporter malfunction and intracellular 
TDF accumulation.[81] The two transporters on the apical surface, MRP 2 and 4, are 
coded for by the ABCC2 and ABCC4 genes.[82, 93] Genetic polymorphisms in the 
ABCC2 – encoding MRP 2 - are associated with the development of proximal tubular 
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dysfunction but there is no association between proximal tubulopathy and genetic 
polymorphisms in the ABCC4 gene.[82, 93] Interestingly, MRP 4 is described as the 
transporter that extrudes TDF from the proximal tubules rather than MRP 2. Although 
the mechanism by which defective MRP 2 causes TDF accumulation is poorly 
understood, it is postulated that MRP 2 may have a complimentary role to MRP 4 in 
TDF transport or alternatively excretes an unknown co-factor that drives TDF induced 
mitochondrial toxicity.[82]  
1.5 Summary 
As more patients are being exposed to TDF questions exist regarding its association 
with AKI in the South African clinical setting. Little is known of this relationship 
with only two studies examining South African patients initiated on TDF in the 
ambulatory setting.[74, 77] Evidence suggests that AKI associated with TDF use is 
multifactorial, and occurs in patients with several predisposing factors but it is 
possible that a genetic predisposition, due to polymorphisms, play a role in TDF 
related nephrotoxicity.[11] As limited data describing TDF and AKI in South African 
HIV positive patients exists, this study will characterize this association, in particular: 
to describe presentation, severity and risk factors and assess short-term survival and  
response to treatment.  
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Objectives 
To describe the aetiology and spectrum of renal disease observed in adult hospitalized 
HIV-infected patients. 
Specific Aims: 
1. To describe the patient population and disease patterns in patients presenting with 
acute renal failure whilst on a TDF based ART Regimen with respect to the 
following variables:  
o Demographics  
o Co-morbidities  
o Stage of HIV infection 
2. To assess the proportion of those with acute renal failure and receiving ART as:  
i. Immediate (less than 6 weeks after ART initiation) 
ii. Intermediate (6 weeks - 6months after ART initiation) 
iii. Delayed (>6 months after ART initiation) 
3. To compare the patient population and disease patterns in patients with acute renal 
failure exposed to TDF to all other HIV positive patients not exposed to TDF with 
renal failure.  
The TDF - exposed group is as follows: 
• Those currently on TDF based ART  
• Those who have defaulted TDF for less than 1 week 
The Non - TDF exposed group is as follows: 
• Those presenting with renal failure on non-TDF based ART 
• Those who have defaulted non-TDF based ART for any period of time  
• Those who have defaulted TDF based ART for more than 1 week  
• Those not on ART  
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4. To assess short-term survival and response to treatment in HIV positive patients 
exposed to TDF with acute renal failure  
Methodology 
1.Study design 
A prospective case cohort study with descriptive and comparative elements 
2.Study population and sample 
2.1 LOCATION & DURATION 
The study is a single-centre study and will take place at Klerksdorp/Tshepong 
Hospital.  
2.2 POPULATION 
The study will recruit patients admitted to the Klerksdorp/Tshepong hospital who are 
HIV positive and present with acute renal failure.  
INCLUSION CRITERIA 
1. Age Older than 18 
2. Confirmed HIV positive diagnosis (hard copy dated documentation of one of 
the following: ART treatment, positive HIV ELISA, positive double rapid 
HIV antibody tests, detectable HIV viral load)  
3. Acute Renal failure as defined by one or more of the following: 
a. Creatinine increase by > 26.4umol/l above:  
i. The upper limit of normal (as per the local laboratory 
standards)   
ii. A recent normal Creatinine level prior to admission 
b. Creatinine increase by more than 1.5 times the baseline level (baseline 
taken prior to ARV initiation)  
c. Urine output < 0.5ml/kg/hr for 6 hours 
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d. eGFR decreased by greater than 25% compared to any prior eGFR 
calculation using the Cockroft-Gault Equation[46]  
EXCLUSION CRITERIA 
1. Unable to provide written informed consent  
2. Reluctant to comply with study procedures 
3. Incomplete or insufficient clinical records for collection of parameters to be 
measured, as enlisted in the data sheet. 
4. Known or Newly Diagnosed with Chronic Kidney Disease defined as: 
abnormalities of kidney structure or function, which is present for more than 3 
months, with implications for health evidenced by one or more of the 
following: 
a. eGFR < 60ml/min/1.73m2 for a period of more than 3 months  
b. Proteinuria, urine sediment abnormalities or abnormalities detected by 
imaging or renal biopsy for a period of more than 3 months 
2.3 SAMPLE SIZE AND DURATION 
A sample size of approximately 144 patients prospectively recruited over a 6 month 
period was chosen, based the number of patients admitted to the adult medicine wards 
at the Klerksdorp/Tshepong Hospital Complex per month. We anticipate recruitment 
will take place over a period of 24 weeks.  However, we will continue to recruit 
patients until the target of 144 has been reached.   
Table showing: Projected patient numbers recruited for study  
ADMISSIONS WITH 
RENAL FAILURE PER 
WEEK 
ADMISSIONS WITH RENAL 
FAILURE ON TDF ART PER 
WEEK 
STUDY TIME 
FRAME 
(WEEKS) 
TOTAL 
PATIENTS 
RECRUITED 
6 3 24 144 
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3. Description of methods and techniques 
1. INTERVIEW: Patients will be counseled about the study and written informed 
consent obtained. All patients will then undergo a structured interview. Questions will 
be asked about patient’s demographics, HIV history – including current and previous 
ART use, history of tuberculosis, co-morbid diseases, medication use and traditional 
medicine and possible heavy metal exposure. 
2. LABORATORY INVESTIGATIONS: HIV relevant parameters: the CD4 count 
and HIV viral load will be measured. Biochemical parameters: urea and electrolytes 
will be measured and using the Cockroft-Gault equation the eGFR will be calculated. 
The creatinine and eGFR will be the parameters used to define patients as having 
renal failure. Other investigations will include: calcium, magnesium and phosphate; 
serum ferritin; full blood count and hepatitis B status. Urine parameters will include a 
urine dipsticks, urine protein creatinine ratio, urine for amino acids and phosphate. 
These investigations will be performed prior to any renal specific treatment being 
administered and preferably in the acute phase of presentation. 
3. RADIOLOGICAL INVESTIGATIONS: Renal sonar to determine kidney sizes and 
a Chest X-ray to assess the presence of possible pulmonary tuberculosis.   
4. PATIENT RECORDS: Patient admission medical records will be assessed to 
evaluate if patients are diagnosed or treated for current tuberculosis infection or 
cryptococcal meningitis. Furthermore, the reason for the admission will be abstracted 
from clinical records. 
5. FOLLOW UP: Patients records will be reviewed on discharge and at routine follow 
up at one month, two months and three months following discharge. Repeat urea and 
electrolytes, all treatment received for: HIV, acute renal failure and other intercurrent 
illnesses will be documented.   
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Statistical analysis 
This research project is intended as a pilot study. Aim 1: participant characteristics 
will be analysed descriptively using frequencies and medians and compared between 
renal failures exposed to TDF and renal failures not exposed to TDF using chi-square 
and Kruskall-Wallis tests as appropriate. Aim 2: proportions will be compared using 
the chi-square test of proportions. Aim 3: comparisons will be made using the chi-
square test of proportions and for continuous variables the Kruskall-Wallis non-
parametric test. Aim 4: Kaplan-Meier and Cox regression analysis will be used to 
address short-term survival. A Kaplan Meier graph will be drawn showing time to 
renal failure using: as the start of follow up time - the initiation of ART and the date 
of censoring the date - when symptoms first developed or when the first diagnosis of 
renal failure was made. 
Ethics 
Ethics approval will be obtained from the Human Resource Ethics Committee.  
Consent for the use of patient’s records and will be gained from the Academic Head 
of Internal Medicine and CEO/Superintendent of Klerksdorp/Tshepong Hospital 
Complex. Individual patient consent will be obtained from the patients examined in 
the study. Each data sheet will be assigned a study number. No patient names or 
hospital numbers will be used so patient identity will remain confidential. Data will 
only be made available too the supervisors, primary researcher and statistician. 
Timing 
Gant Chart showing the timeline of the study: 
2014 Mar Apr May Jun Jul Aug Sep Oct Nov Dec 
Literature Review                     
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Preparing Protocol                     
Protocol Assessment                     
Ethics Application                     
Data Collection                     
           2015 Jan Feb Mar Apr May Jun Jul Aug Sep Oct 
Data Collection                     
Data Analysis                     
Writing Up - Thesis                     
 
Funding 
The budget is expected to involve photocopying of data sheets and travelling costs. 
Other costs will include study nurse and counselor and costs of non-routine 
investigations - urine phosphate and amino acids.  
Limitations 
Due to the prospective nature of the study problems may be encountered in finding an 
adequate number of patients to meet the study aims. Furthermore, logistical 
difficulties of travelling from Johannesburg too Klerksdorp may be faced. The sample 
size may not be adequate to identify small differences in the prevalence of risk factors 
for renal failure between groups. 
Note of review recommendations: 
• Eligibility criteria of Non - TDF exposed group: Patients who defaulted TDF for a period of 
more than 1 week be increased to 8 weeks and those who defaulted for 1 – 8 weeks to be 
excluded.  
• Replace the term acute renal failure with acute kidney injury 
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Chapter 2. Manuscript  
Background 
Acute kidney injury (AKI) is a major cause of morbidity and mortality in HIV 
infected individuals.[1-3] Mortality in hospitalized HIV-infected adults is higher in 
those with AKI, whilst in adults living with HIV the risk of kidney disease is almost 
four-fold that of HIV-uninfected adults.[4, 5] Antiretroviral therapy (ART) mitigates 
this risk.[1]  
Numerous studies from developed settings have reported AKI in HIV-infected 
individuals; suggesting that aetiology of AKI is multi-factorial. Moreover both HIV 
and ART are directly nephrotoxic.[1, 4-9] Pre-renal AKI from renal hypoperfusion 
(commonly from gastroenteritis), sepsis induced acute tubular necrosis (ATN) and 
concomitant nephrotoxic drug use are common causes of AKI in HIV positive 
patients.[2, 3, 6, 7, 10-17] Well-described risk factors for AKI apply to both HIV-
seronegative and seropositive individuals.[1, 4-7, 11, 18-21] However, specific risk 
factors in HIV seropositive individuals include: male sex; advanced 
immunosuppression; long term ART use and pre-existing renal disease.[4-7, 11, 18-
23]  
In October 2001, the Food and Drug Administration approved tenofovir (TDF) as the 
first nucleotide reverse-transcriptase inhibitor (NRTI) for the treatment of HIV.[24] 
Since April 2010, TDF has been used as the mainstay of first line ART in South 
Africa, massively increasing the number of South Africans receiving TDF.[25, 26] 
Although not initially reported in the early clinical trials, subsequent case reports, 
case series and observational studies reported TDF associated nephrotoxicity and, in 
2010, a systematic review and meta-analysis reported a significant decline in renal 
function associated with TDF use.[27-42] The mechanism of action appears to be the 
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accumulation of TDF in proximal tubular cells (due primarily to genetic 
polymorphisms encoding defective transmembrane drug transporters), which results 
in mitochondrial toxicity and subsequent renal injury, clinically presenting as Fanconi 
syndrome or ATN with AKI.[9, 38, 43-52] The reported prevalence of TDF-related 
nephrotoxicity is 2.4% occurring at 6 – 9 months following TDF initiation, although 
South African studies suggest earlier onset.[23, 28, 40-42, 47, 53-57] We report the 
presentation, severity and risk factors for AKI in TDF-exposed South African 
patients, and assess response to treatment and short-term outcomes.  
Methods 
This prospective case cohort study was a primary data collection, overseen and 
conducted by the first author (FS), and recruited patients from the 
Klerksdorp/Tshepong Hospital Complex, a secondary level public hospital in South 
Africa’s North West province, from October 2014 to June 2015. We enrolled HIV-
infected patients admitted to the adult medicine wards with AKI, and compared those 
exposed to TDF to those who had not received TDF and followed them up after 
discharge. Eligible patients were: hospitalized, HIV-infected adults, ≥18 years of age 
with a diagnosis of AKI. We excluded patients with prior or pre-existing kidney 
disease (either self-reported or as indicated by medical records or laboratory results). 
Those who appeared unwilling or incapable of attending follow up, and those whose 
clinical records were inadequate to assess renal function or HIV treatments prior to 
the study were also excluded. The University of Witwatersrand Human Research 
Ethics Committee approved this study.  
Study Definitions and Measures 
Patients were categorized as TDF-exposed if they were on TDF-based ART at the 
time of admission, or had defaulted TDF for less than 1 week prior to admission. The 
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TDF unexposed group included individuals who: were ART naïve, were taking non-
TDF ART, had defaulted non-TDF based ART for any duration, and those who had 
defaulted TDF based ART for at least 8 weeks prior to the onset of AKI.  
In all study patients, AKI was diagnosed and staged according to the Kidney Disease 
Improving Global Outcomes (KDIGO) 2012 Clinical Practice AKI Guideline.[58] 
Baseline serum creatinine (SCr) prior to AKI was determined either by a SCr taken 
prior to, but within the preceding year, of admission, or the lowest normal SCr at 
discharge or on follow up.[59, 60] If no baseline SCr was available, an estimated 
baseline SCr was calculated based on a Modification of Diet in Renal Disease 
Equation (MDRD) eGFR of 75ml/min per 1.73m2.[58, 61, 62] Renal recovery was 
defined as a decreasing SCr over time and no need for continuing renal replacement 
therapy (RRT); and was categorized as complete (SCr recovery below 1.5 times the 
baseline) or partial (SCr recovery above 1.5 times the baseline).[63, 64] New 
admissions to the acute care adult medical ward were screened for eligibility on 
weekdays. If eligible, written informed consent was obtained and a structured 
interview administered assessing: ART use, previous tuberculosis (TB) history, co-
morbidities, concomitant gastrointestinal symptoms, drug history and other important 
exposures; necessary blood and urine samples were taken, results of radiological 
investigations recorded and relevant information from clinical records noted. On 
discharge, a summary of the clinical course of the patient was abstracted from the 
medical records. Patients were then actively followed up at a visit scheduled 3 months 
after discharge. 
Statistical Analysis 
Patient demographic and clinical characteristics are reported as medians and 
interquartile ranges (IQR) for continuous variables and proportions with 95% 
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confidence intervals for categorical variables. These were compared between groups 
using the Mann – Whitney, Kruskal-Wallis and Chi – square tests as appropriate. All 
statistical analyses were performed using Statistica version 12 (StatSoft). 
Results 
From 1 October 2014 to 30 June 2015, 199 HIV-infected patients with presumed AKI 
were enrolled in this study, 24 were subsequently excluded as they either had prior 
kidney disease (16) or had defaulted TDF-based ART for less than 8 weeks (8). Of 
the remaining 175, their median age was 41years (IQR 35-50); 61% were women; 
virtually all (99%) were black Africans; their median BMI was 21kg/m2 (IQR 19-24) 
on admission (Table 1). Ninety-three (53%) were TDF-exposed for a median 
treatment duration of 30 weeks (IQR 8-61) of whom 27 (29%) had prior ART 
exposure before switching to a TDF containing regimen. The majority of the TDF 
group (94%) received a concomitant non-nucleoside reverse transcriptase inhibitor 
(NNRTI) and 6% a protease inhibitor (PI). Thirty-one patients in the non-TDF group 
were receiving ART for a median duration of 306 weeks (IQR 88-729); 62% of the 
non-TDF group was ART-naïve on admission. .  
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Table 1: Baseline demographic characteristics, co-morbidities, risk factors and laboratory characteristics in acute kidney injury 
(AKI) patients at admission stratified by TDF exposure (n=175) 
  TDF   NON TDF   p -value 
  93 (53) 82 (47)   
Demographics       
Age (yrs) [median (IQR)] 42 (35 - 53) 40 (35 - 49) 0.260 
Female [n (%)] 62 (67) 45 (55) 0.110 
Black [n (%)] 91 (98) 83 (100) 0.182 
Serum Electrolytes       
Potassium (mmol/L) [median(IQR)] 4.1 (3.3 - 5.1) 4.3 (3.5-5.2) 0.348 
Bicarbonate (umol/L) [median(IQR)] 14 (10 - 18) 16 (13 - 19) 0.047 
Phosphate (mmol/L) [median(IQR)] 1.2 (0.8 - 1.7) 1.3 ( 0.9 - 1.6) 0.496 
Renal Parameters 
  
  
Admission Creatinine (umol/L) [median(IQR)] 282 (172 - 542) 189 (146 - 343) 0.007 
Admission eGFR - CKD - EPI (mL/min per 1.73m2) [median(IQR)] 14.2 (4.3 - 28) 25.6 (10.4 - 39.5) 0.002 
Baseline Creatinine (umol/L) [median(IQR)] 77 (65 - 88) 77 (62 - 92) 0.920 
Urine Protein:Creatinine Ratio (g/mmol creat) [median(IQR)] 0.212 (0.111 - 0.316) 0.128 (0.087 - 0.212) 0.003 
Normoglycemic glycosuria [n (%)] 7 (11) 6 (10) 0.863 
Hyperechoiec  [n(%)] 71 (91) 48 (84) 0.226 
Right kidney size (cm) [median(IQR)] 11,25 (10,3 - 12,2) 11 (10,2 - 11,8) 0.347 
Left kidney size (cm) [median(IQR)] 11,4 (10,7 - 12,3) 11 (10,4 - 11,8) 0.135 
Co-morbidities       
Hypertension [n(%)] 22 (24) 16 (20) 0.507 
Diabetes [n(%)] 8 (9) 3 (4) 0.179 
Hepatitis B Positive [n(%)] 11 (12) 9 (11) 0.86 
Risk factors       
Tuberculosis (TB) [n(%)]       
Completed TB treatment before admission 35 (38) 34 (41) 0.605 
Newly diagnosed TB  46 (50) 45 (55) 0.474 
Sputum or culture proven tuberculosis  22 (48) 22 (49) 0.919 
Pneumonia  [n(%)] 9 (10) 12 (17) 0.148 
Sepsis [n(%)] 4 (4) 7 (9) 0.249 
Vomiting [n(%)] 32 (34) 14 (17) 0.009 
Diarrhoea [n(%)] 36 (39) 17 (21) 0.008 
Non-steroidal anti-inflammatory drugs use [n(%)] 26 (28) 30 (37) 0.784 
HIV-related and infective parameters       
CD4 Count (cells/mm3) [median(IQR)] 147 (57 - 304) 87 (41 - 210) 0.067 
HIV Viral Load (copies/ml)       
Virally suppressed (LDL or < 1000 [n(%)]) 56 (60) 14 (17) <0.001 
Median HIV Viral load in those > 1000 [median(IQR)] 
39456 (4537 - 
326300) 
414365 (110159 - 
1521015) <0.001 
Haemoglobin (g/dl) [median(IQR)] 9.6 (7.8 - 11.3) 9.8 (7.4 - 12) 0.622 
C-reactive protein (mg/L) [medain(IQR)] 127 (39 - 189) 89 (37 - 180) 0.386 
Albumin (g/L) [median(IQR)] 20 (16 - 24) 18 (15 - 23) 0.122 
Ferritin (ug/L) [median(IQR)] 490 (205 - 1171) 750 (366 - 1415) 0.047 
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AKI severity and measures of kidney disease 
Half (53%) of all participants had severe AKI, most were in the TDF group (62%; 
n=57); whereas mild AKI was predominant in the non-TDF group (62%; n=23) 
(Figure 1). The TDF group had: a higher median admission SCr (282umol/L; IQR 
172-542 vs 189umol/L IQR 146-343; p=0.007); higher median urine protein 
creatinine ratio (0.212g/mmol creat; IQR 0.111-0.316 vs 0.128g/mmol creat; IQR 
0.087-0.212; p=0.003); a lower median eGFR (CKD-EPI) (14.2mL/min; IQR 4.3-28 
vs 25.6mL/min; IQR 10.4-39.5; p=0.002) and was more acidotic (serum bicarbonate 
14umol/L; IQR 10-18 vs 16umol/L; IQR 13-19; p=0.047). Markers of proximal 
tubular dysfunction (urine phosphaturia and glycosuria, serum hypophosphatemia and 
hypokalemia) were not markedly deranged in either group. Laboratory results 
suggestive of interstitial nephritis were present in many, with high rates of 
leucocyturia (n=47; 32%) and hematuria (n= 81; 55%) in sterile urine specimens, but 
there was no significant difference in rates in the two groups - only 29 (17%) of all 
patients had culture positive urinary tract infections. 
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Figure	1:	Severity	of	acute	kidney	injury	on	admission	stratified	by	TDF	exposure		
Co-morbidities and risk factors for AKI 
Half of both groups (50% TDF vs 55% non-TDF; p=0.474) were newly diagnosed 
with TB, and overall a prior history of TB treatment was reported by 39%. 
Gastrointestinal symptoms, vomiting and diarrhea were reported more frequently in 
the TDF group (39% v 21%; p=0.008) and, twice as many patients in the TDF group 
reported chronic diarrhea (p=0.522). Regarding hemodynamic status, using clinical 
and biochemical parameters, there was no statistically significant difference between 
the two groups. Non-infectious co-morbidities such as hypertension (22%) and 
diabetes (6%) were reported at similar rates in both groups. Receipt of traditional 
medication was infrequently self-reported but high rates of non-steroidal anti-
inflammatory drug (NSAID) use, within the month prior to admission, was reported 
by both groups. Rates of exposure to other nephrotoxins, such as amphotericin B, 
were similar in both groups. A higher proportion of TDF-exposed patients were 
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virally suppressed than ART-treated patients from the non-TDF group (p=0. 017); and 
in those not suppressed, the median viral load was lower in the TDF group (p=0.002).  
Treatment and outcomes 
The overwhelming majority of patients received intravenous fluid therapy (96%) and 
only seven received RRT; 85% of all patients recovered sufficiently to be discharged 
from hospital. Even though the median length of hospital stay was the same in both 
groups (9 days), the TDF group had delayed renal recovery with higher SCr on 
discharge: median SCr 120umol/L; IQR 87-240 vs 97umol/L; IQR 75-137; p=0.032 
(Figure 2). Moreover, a smaller proportion of TDF exposed patients had complete 
renal recovery at the 3-month post-discharge follow-up visit (61% vs 78%; p=0.043) 
(Table 2). Although TDF was stopped on admission in all patients, at 3-month follow 
up 55 patients (31%) had been re-started on full dose TDF-based ART without 
apparent adverse effects, 38 (22%) of whom had been TDF-exposed on admission. 
Only 1 patient who was re-initiated on TDF was subsequently changed to non-TDF 
based ART. No significant difference in renal recovery (p=0.114) or mortality 
(p=0.105) at 3-month follow-up was found in those re-initiated on TDF compared to 
those where non-TDF based ART was used following discharge.  
In those who died during their hospital stay, no difference was noted in either SCr 
values measured prior to death or on renal recovery when comparing the TDF and 
non-TDF groups. (Table 2) Fifty-five percent of deaths occurred in-hospital and they 
had a higher median serum SCr prior to death compared to the median SCr at 
discharge in survivors (p<0.001). Furthermore, most patients who died in hospital had 
severe AKI immediately prior to death (p<0.001).  
Sixteen (9.1%) patients were lost to follow-up after discharge. In those who died 
following discharge, similar mortality rates were found in both groups (p=0.383). 
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When assessing overall outcome, from admission to 3-month follow-up, the mortality 
rate in both groups was 27% but the duration from admission to death and discharge 
to death was significantly shorter in the TDF group (Table 2). Seventy percent (n=33) 
of those who died were newly diagnosed with TB compared to 42% of survivors 
(p=0.001). Similarly, elevated CRP and anaemia were more frequently found in 
patients who died in this cohort.   
 
 
Figure	2:	Comparison	of	median	serum	creatinine	(SCr)	values	stratified	by	TDF	
exposure	at	various	time	intervals:		Baseline	prior	to	admission;	On	admission;	On	
discharge;	In	survivors	to	discharge	and	In	deaths	during	hospital	stay.	
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Table 2: Outcomes of mortality, renal recovery and co-morbidities measured at discharge and 3-month 
follow up startified by TDF exposure (n=175) 
  TDF   NON TDF   p -value 
  93 (53) 82 (47)   
Mortality at discharge       
Deceased [n (%)] 16 (17) 10 (12) 0.353 
Fluid therapy alone [n (%)] 88 (95) 80 (98) 0.322 
Deceased [n (%)] 13 (15) 9 (11) 0.499 
Fluid and Renal replacement therapy [n(%)] 5 (5) 2 (2) 0.322 
Deceased [n (%)] 3 (60) 1 (50) 0.809 
Duration of stay (days) [median[IQR])       
If Survived 9 (7-15) 9 (7-14) 0.722 
If Deceased 10 (6-16) 13 (9-16) 0.286 
Mortality after 3-month follow up       
Deceased [n (%)] 25 (27) 22 (27) 0.921 
Duration to death (days) (median[IQR])       
Admission to death 30 (13-40) 64 (57-129) 0.049 
Discharge to death 24 (18-30) 52 (47-122) 0.016 
Renal parameters on discharge       
Renal recovery amongst deceased [n (%)]       
Complete creatinine recovery 3 (20) 1 (10) 0.504 
Partial creatinine recovery 7 (47) 5 (50) 0.870 
Worsening Creatinine 5 (33) 4 (40) 0.734 
Renal recovery amongst survivors [n (%)]       
Complete creatinine recovery 37 (48) 39 (54) 0.456 
Partial creatinine recovery 32 (42) 19 (26) 0.051 
Creatinine at death by renal recovery  (umol/L) 
[median(IQR)]       
Deceased and complete recovery 79 (78 - 83) 92 (92 - 92) 0.5 
Deceased and partial recovery 283 (131 - 368) 271 (139 - 513) 1 
Deceased and worsening creatinine 572 (527 - 627) 388 (366 - 577) 0.413 
Renal parameters after 3-month follow up       
Renal Recovery amongst survivors [n (%)]       
Complete creatinine recovery 37 (61) 40 (78) 0.043 
Partial creatinine recovery 9 (15) 2 (4) 0.055 
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Discussion 
This prospective cohort suggests that HIV-infected patients with AKI who also 
received TDF ART had more severe AKI and a higher presenting median SCr 
compared to those on non-TDF ART. Moreover, the renal recovery was slower in 
those taking TDF. In-hospital outcomes, duration of admission, and overall mortality, 
however, were similar in both TDF-exposed and unexposed groups. AKI in HIV-
infected individuals has a poor prognosis, as more than a quarter of patients in this 
cohort died.     
In our study TDF-exposed HIV-infected patients who develop AKI have similar 
aetiology and rate and range of nephrotoxic risk factors that we measured, as those 
not receiving TDF. However, our data suggests that TDF has an added nephrotoxic 
effect in patients with AKI, causing more rapid worsening of renal function and 
higher proportions with proteinuria and acidosis, and appears to delay recovery.    
The data on TDF use and AKI in Southern Africa is limited; previous studies in 
ambulatory patients report a frequency of TDF-associated nephrotoxicity of just under 
3% with pre-existing renal dysfunction, anaemia and immunosuppression risk factors 
for nephrotoxicity with TDF use.[55, 56] This study is the first we are aware of that 
reports AKI, stratified by TDF exposure, in hospitalized HIV positive patients in 
South Africa, and is particularly relevant due to the massive increase in prescriptions 
of TDF as part of first line ART in the country.[26]  
Renal replacement therapy use was limited in this cohort, despite increasing SCr in 
over a third of those who died during admission, and despite no formal restrictions or 
eligibility criteria for the initiation of RRT in this setting. We postulate that RRT may 
have prevented some deaths. Moreover, the substantial mortality following discharge 
from hospital suggests that more intensive monitoring and follow-up after discharge 
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from hospital is necessary in all patients with AKI. Further studies are required to 
assess the likely causes of, and contributors to death, and to better identify potential 
interventions to prevent mortality. Consistent with our findings, international studies 
have reported the duration of TDF exposure prior to onset of decline in renal function 
to be 6 - 9 months [41, 54], although studies of ambulatory patients in South Africa 
report a shorter median time to nephrotoxicity (3.6 months).[55, 56] Current 
recommendations suggest that TDF dose adjustment is necessary in those with renal 
injury whilst on TDF.[65] Although published literature reports male gender and 
lower body weight as risk factors associated with AKI [17, 41, 42, 54, 56], the high 
proportion of women with AKI that we report is likely due to higher seroprevelance 
of HIV amongst South African women and national policy to initiate ART in all HIV-
positive pregnant women irrespective of CD4 count.[26, 66]  The apparent role of TB, 
which was frequently diagnosed in this cohort, in contributing to both morbidity and 
mortality following discharge, is substantial. The association between AKI and TB is 
described in a retrospective cohort from Johannesburg, in whom 26% of HIV positive 
patients with AKI were diagnosed with TB, almost half what we report.[14] However, 
over half of the cases of TB we report were not laboratory confirmed.[67] 53% of our 
cohort had laboratory findings suggestive of interstitial nephritis, which could be at 
least partially attributed to TB and/or NSAID use, although this finding is limited by 
the absence of renal biopsies in this cohort.[68, 69] Whilst the immune re-constitution 
syndrome (IRIS) is a known cause of an interstitial nephritis, the duration of ART 
exposure in the majority of our patients was for a period longer than that associated 
with the onset of IRIS; moreover, some patients were ART naive.[69, 70] 
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Limitations 
This study has several limitations. We restricted our sample to patients admitted to a 
single regional hospital in South Africa and we are unable to report the overall rate of 
AKI in TDF and other ART recipients. Furthermore, the incidence or prevalence of 
AKI relative to all HIV positive admissions was not measured, nor is there reliable 
data on which to base an estimate of incidence or prevalence. Tubular dysfunction 
using urine beta-2 microglobulin and fractional excretion of phosphate was not 
measured and, in some patients, not every study parameter was measured but all had 
sufficient measured data to be eligible for inclusion. Baseline SCr values were not 
available in all patients and missing baseline values were inferred using the MDRD 
formula (calculated using an eGFR of 75ml/min/ 1.73m2); this may have biased the 
classification of AKI severity in both the TDF, but particularly in the non – TDF 
group where baseline SCr levels were less readily available as ART-naïve patients 
infrequently had a measured SCr prior to admission or on follow-up.[60, 71] 
Furthermore, no renal biopsies were performed in this cohort, particularly in those 
with partial renal recovery, however in most instances the aetiology of AKI was 
clinically evident.   
Conclusion 
Comparison of the two groups suggests that risks factors, aetiology and mortality of 
AKI in HIV infected in-patients, irrespective of TDF use, is similar but that co -
existing TDF use appears to result in more severe and longer lasting AKI. Our 
findings suggest that a lower threshold for RRT may be needed in those with limited 
or no SCr recovery and intensive follow after discharge from hospital may reduce 
mortality in all HIV-infected AKI patients, and especially in those with concomitant 
TB. 
	 49	
References – (Manuscript) 1.	 Wyatt	CM,	Arons	RR,	Klotman	PE,	Klotman	ME.	Acute	renal	failure	in	hospitalized	patients	with	HIV:	risk	factors	and	impact	on	in-hospital	mortality.	AIDS	2006,20:561-565.	2.	 Cohen	SD,	Chawla	LS,	Kimmel	PL.	Acute	kidney	injury	in	patients	with	human	immunodeficiency	virus	infection.	Curr	Opin	Crit	Care	2008,14:647-653.	3.	 Kalim	S,	Szczech	LA,	Wyatt	CM.	Acute	kidney	injury	in	HIV-infected	patients.	Semin	Nephrol	2008,28:556-562.	4.	 Choi	AI,	Li	Y,	Parikh	C,	Volberding	PA,	Shlipak	MG.	Long-term	clinical	consequences	of	acute	kidney	injury	in	the	HIV-infected.	Kidney	Int	2010,78:478-485.	5.	 Islam	FM,	Wu	J,	Jansson	J,	Wilson	DP.	Relative	risk	of	renal	disease	among	people	living	with	HIV:	a	systematic	review	and	meta-analysis.	BMC	Public	
Health	2012,12:234.	6.	 Franceschini	N,	Napravnik	S,	Eron	JJ,	Jr.,	Szczech	LA,	Finn	WF.	Incidence	and	etiology	of	acute	renal	failure	among	ambulatory	HIV-infected	patients.	Kidney	Int	2005,67:1526-1531.	7.	 Roe	J,	Campbell	LJ,	Ibrahim	F,	Hendry	BM,	Post	FA.	HIV	care	and	the	incidence	of	acute	renal	failure.	Clin	Infect	Dis	2008,47:242-249.	8.	 Gerntholtz	TE,	Goetsch	SJ,	Katz	I.	HIV-related	nephropathy:	a	South	African	perspective.	Kidney	Int	2006,69:1885-1891.	9.	 Roling	J,	Schmid	H,	Fischereder	M,	Draenert	R,	Goebel	FD.	HIV-associated	renal	diseases	and	highly	active	antiretroviral	therapy-induced	nephropathy.	Clin	Infect	Dis	2006,42:1488-1495.	
	 50	
10.	 Perazella	MA.	Acute	renal	failure	in	HIV-infected	patients:	a	brief	review	of	common	causes.	Am	J	Med	Sci	2000,319:385-391.	11.	 Lopes	JA,	Melo	MJ,	Viegas	A,	Raimundo	M,	Camara	I,	Antunes	F,	et	al.	Acute	kidney	injury	in	hospitalized	HIV-infected	patients:	a	cohort	analysis.	
Nephrol	Dial	Transplant	2011,26:3888-3894.	12.	 Naicker	S,	Aboud	O,	Gharbi	MB.	Epidemiology	of	acute	kidney	injury	in	Africa.	Semin	Nephrol	2008,28:348-353.	13.	 Fabian	J,	Naicker	S.	HIV	and	kidney	disease	in	sub-Saharan	Africa.	Nat	Rev	
Nephrol	2009,5:591-598.	14.	 Vachiat	AI,	Musenge	E,	Wadee	S,	Naicker	S.	Renal	failure	in	HIV-positive	patients—a	South	African	experience.	Clin	Kidney	J	2013,0:1-6.	15.	 Arendse	CG,	Wearne	N,	Okpechi	IG,	Swanepoel	CR.	The	acute,	the	chronic	and	the	news	of	HIV-related	renal	disease	in	Africa.	Kidney	Int	2010,78:239-245.	16.	 Fine	DM,	Perazella	MA,	Lucas	GM,	Atta	MG.	Renal	disease	in	patients	with	HIV	infection:	epidemiology,	pathogenesis	and	management.	Drugs	2008,68:963-980.	17.	 Franey	C,	Knott	D,	Barnighausen	T,	Dedicoat	M,	Adam	A,	Lessells	RJ,	et	al.	Renal	impairment	in	a	rural	African	antiretroviral	programme.	BMC	Infect	
Dis	2009,9:143.	18.	 Lopes	JA,	Fernandes	J,	Jorge	S,	Neves	J,	Antunes	F,	Prata	MM.	Acute	renal	failure	in	critically	ill	HIV-infected	patients.	Crit	Care	2007,11:404.	19.	 Lopes	JA,	Melo	MJ,	Raimundo	M,	Fragoso	A,	Antunes	F.	Long-term	risk	of	mortality	for	acute	kidney	injury	in	HIV-infected	patients:	a	cohort	analysis.	BMC	Nephrol	2013,14:32.	
	 51	
20.	 Miro	JM,	Cofan	F,	Trullas	JC,	Manzardo	C,	Cervera	C,	Tuset	M,	et	al.	Renal	dysfunction	in	the	setting	of	HIV/AIDS.	Curr	HIV/AIDS	Rep	2012,9:187-199.	21.	 Franceschini	N,	Napravnik	S,	Finn	WF,	Szczech	LA,	Eron	JJ,	Jr.	Immunosuppression,	hepatitis	C	infection,	and	acute	renal	failure	in	HIV-infected	patients.	J	Acquir	Immune	Defic	Syndr	2006,42:368-372.	22.	 Peraldi	MN,	Maslo	C,	Akposso	K,	Mougenot	B,	Rondeau	E,	Sraer	JD.	Acute	renal	failure	in	the	course	of	HIV	infection:	a	single-institution	retrospective	study	of	ninety-two	patients	anad	sixty	renal	biopsies.	
Nephrol	Dial	Transplant	1999,14:1578-1585.	23.	 Wikman	P,	Safont	P,	Del	Palacio	M,	Moreno	A,	Moreno	S,	Casado	JL.	The	significance	of	antiretroviral-associated	acute	kidney	injury	in	a	cohort	of	ambulatory	human	immunodeficiency	virus-infected	patients.	Nephrol	
Dial	Transplant	2013,28:2073-2081.	24.	 DeChristoforo	R,	Penzak	SR.	Tenofovir:	a	nucleotide	analogue	reverse-transcriptase	inhibitor	for	treatment	of	HIV	infection.	Am	J	Health	Syst	
Pharm	2004,61:86-98;	quiz	99-100.	25.	 The	South	African	antiretroviral	treatment	guidelines.	In:	Department	of	Health;	2010.	pp.	1-7.	26.	 The	South	African	antiretroviral	treatment	guidelines.	In:	Department	of	Health;	2013.	pp.	1-10.	27.	 Schooley	RT,	Ruane	P,	Myers	RA,	Beall	G,	Lampiris	H,	Berger	D,	et	al.	Tenofovir	DF	in	antiretroviral-experienced	patients:	results	from	a	48-week,	randomized,	double-blind	study.	Aids	2002,16:1257-1263.	
	 52	
28.	 Izzedine	H,	Hulot	JS,	Vittecoq	D,	Gallant	JE,	Staszewski	S,	Launay-Vacher	V,	
et	al.	Long-term	renal	safety	of	tenofovir	disoproxil	fumarate	in	antiretroviral-naive	HIV-1-infected	patients.	Data	from	a	double-blind	randomized	active-controlled	multicentre	study.	Nephrol	Dial	Transplant	2005,20:743-746.	29.	 Barditch-Crovo	P,	Deeks	SG,	Collier	A,	Safrin	S,	Coakley	DF,	Miller	M,	et	al.	Phase	i/ii	trial	of	the	pharmacokinetics,	safety,	and	antiretroviral	activity	of	tenofovir	disoproxil	fumarate	in	human	immunodeficiency	virus-infected	adults.	Antimicrob	Agents	Chemother	2001,45:2733-2739.	30.	 Karras	A,	Lafaurie	M,	Furco	A,	Bourgarit	A,	Droz	D,	Sereni	D,	et	al.	Tenofovir-related	nephrotoxicity	in	human	immunodeficiency	virus-infected	patients:	three	cases	of	renal	failure,	Fanconi	syndrome,	and	nephrogenic	diabetes	insipidus.	Clin	Infect	Dis	2003,36:1070-1073.	31.	 Schaaf	B,	Aries	SP,	Kramme	E,	Steinhoff	J,	Dalhoff	K.	Acute	renal	failure	associated	with	tenofovir	treatment	in	a	patient	with	acquired	immunodeficiency	syndrome.	Clin	Infect	Dis	2003,37:e41-43.	32.	 Barrios	A,	Garcia-Benayas	T,	Gonzalez-Lahoz	J,	Soriano	V.	Tenofovir-related	nephrotoxicity	in	HIV-infected	patients.	AIDS	2004,18:960-963.	33.	 Malik	A,	Abraham	P,	Malik	N.	Acute	renal	failure	and	Fanconi	syndrome	in	an	AIDS	patient	on	tenofovir	treatment--case	report	and	review	of	literature.	J	Infect	2005,51:E61-65.	34.	 Verhelst	D,	Monge	M,	Meynard	JL,	Fouqueray	B,	Mougenot	B,	Girard	PM,	et	
al.	Fanconi	syndrome	and	renal	failure	induced	by	tenofovir:	a	first	case	report.	Am	J	Kidney	Dis	2002,40:1331-1333.	
	 53	
35.	 Coca	S,	Perazella	MA.	Rapid	communication:	acute	renal	failure	associated	with	tenofovir:	evidence	of	drug-induced	nephrotoxicity.	Am	J	Med	Sci	2002,324:342-344.	36.	 Rifkin	BS,	Perazella	MA.	Tenofovir-associated	nephrotoxicity:	Fanconi	syndrome	and	renal	failure.	Am	J	Med	2004,117:282-284.	37.	 Peyriere	H,	Reynes	J,	Rouanet	I,	Daniel	N,	de	Boever	CM,	Mauboussin	JM,	
et	al.	Renal	tubular	dysfunction	associated	with	tenofovir	therapy:	report	of	7	cases.	J	Acquir	Immune	Defic	Syndr	2004,35:269-273.	38.	 Woodward	CL,	Hall	AM,	Williams	IG,	Madge	S,	Copas	A,	Nair	D,	et	al.	Tenofovir-associated	renal	and	bone	toxicity.	HIV	Med	2009,10:482-487.	39.	 Creput	C,	Gonzalez-Canali	G,	Hill	G,	Piketty	C,	Kazatchkine	M,	Nochy	D.	Renal	lesions	in	HIV-1-positive	patient	treated	with	tenofovir.	Aids	2003,17:935-937.	40.	 Cooper	RD,	Wiebe	N,	Smith	N,	Keiser	P,	Naicker	S,	Tonelli	M.	Systematic	review	and	meta-analysis:	renal	safety	of	tenofovir	disoproxil	fumarate	in	HIV-infected	patients.	Clin	Infect	Dis	2010,51:496-505.	41.	 Nelson	MR,	Katlama	C,	Montaner	JS,	Cooper	DA,	Gazzard	B,	Clotet	B,	et	al.	The	safety	of	tenofovir	disoproxil	fumarate	for	the	treatment	of	HIV	infection	in	adults:	the	first	4	years.	Aids	2007,21:1273-1281.	42.	 Young	B,	Buchacz	K,	Baker	RK,	Moorman	AC,	Wood	KC,	Chmiel	J,	et	al.	Renal	function	in	Tenofovir-exposed	and	Tenofovir-unexposed	patients	receiving	highly	active	antiretroviral	therapy	in	the	HIV	Outpatient	Study.	
J	Int	Assoc	Physicians	AIDS	Care	(Chic)	2007,6:178-187.	
	 54	
43.	 Fernandez-Fernandez	B,	Montoya-Ferrer	A,	Sanz	AB,	Sanchez-Nino	MD,	Izquierdo	MC,	Poveda	J,	et	al.	Tenofovir	nephrotoxicity:	2011	update.	AIDS	
Res	Treat	2011,2011:354908.	44.	 Hall	AM,	Hendry	BM,	Nitsch	D,	Connolly	JO.	Tenofovir-associated	kidney	toxicity	in	HIV-infected	patients:	a	review	of	the	evidence.	Am	J	Kidney	Dis	2011,57:773-780.	45.	 Perazella	MA.	Tenofovir-induced	kidney	disease:	an	acquired	renal	tubular	mitochondriopathy.	Kidney	Int	2010,78:1060-1063.	46.	 Labarga	P,	Barreiro	P,	Martin-Carbonero	L,	Rodriguez-Novoa	S,	Solera	C,	Medrano	J,	et	al.	Kidney	tubular	abnormalities	in	the	absence	of	impaired	glomerular	function	in	HIV	patients	treated	with	tenofovir.	Aids	2009,23:689-696.	47.	 Horberg	M,	Tang	B,	Towner	W,	Silverberg	M,	Bersoff-Matcha	S,	Hurley	L,	
et	al.	Impact	of	tenofovir	on	renal	function	in	HIV-infected,	antiretroviral-naive	patients.	J	Acquir	Immune	Defic	Syndr	2010,53:62-69.	48.	 Izzedine	H,	Launay-Vacher	V,	Isnard-Bagnis	C,	Deray	G.	Drug-induced	Fanconi's	syndrome.	Am	J	Kidney	Dis	2003,41:292-309.	49.	 Kohler	JJ,	Hosseini	SH,	Hoying-Brandt	A,	Green	E,	Johnson	DM,	Russ	R,	et	
al.	Tenofovir	renal	toxicity	targets	mitochondria	of	renal	proximal	tubules.	Lab	Invest	2009,89:513-519.	50.	 Izzedine	H,	Hulot	JS,	Villard	E,	Goyenvalle	C,	Dominguez	S,	Ghosn	J,	et	al.	Association	between	ABCC2	gene	haplotypes	and	tenofovir-induced	proximal	tubulopathy.	J	Infect	Dis	2006,194:1481-1491.	51.	 Rodriguez-Novoa	S,	Labarga	P,	Soriano	V,	Egan	D,	Albalater	M,	Morello	J,	
et	al.	Predictors	of	kidney	tubular	dysfunction	in	HIV-infected	patients	
	 55	
treated	with	tenofovir:	a	pharmacogenetic	study.	Clin	Infect	Dis	2009,48:e108-116.	52.	 Bickel	M,	Khaykin	P,	Stephan	C,	Schmidt	K,	Buettner	M,	Amann	K,	et	al.	Acute	kidney	injury	caused	by	tenofovir	disoproxil	fumarate	and	diclofenac	co-administration.	HIV	Med	2013,14:633-638.	53.	 Antoniou	T,	Raboud	J,	Chirhin	S,	Yoong	D,	Govan	V,	Gough	K,	et	al.	Incidence	of	and	risk	factors	for	tenofovir-induced	nephrotoxicity:	a	retrospective	cohort	study.	HIV	Med	2005,6:284-290.	54.	 Madeddu	G,	Bonfanti	P,	De	Socio	GV,	Carradori	S,	Grosso	C,	Marconi	P,	et	
al.	Tenofovir	renal	safety	in	HIV-infected	patients:	results	from	the	SCOLTA	Project.	Biomed	Pharmacother	2008,62:6-11.	55.	 Brennan	A,	Evans	D,	Maskew	M,	Naicker	S,	Ive	P,	Sanne	I,	et	al.	Relationship	between	renal	dysfunction,	nephrotoxicity	and	death	among	HIV	adults	on	tenofovir.	AIDS	2011,25:1603-1609.	56.	 Kamkuemah	M,	Kaplan	R,	Bekker	LG,	Little	F,	Myer	L.	Renal	impairment	in	HIV-infected	patients	initiating	tenofovir-containing	antiretroviral	therapy	regimens	in	a	Primary	Healthcare	Setting	in	South	Africa.	Trop	
Med	Int	Health	2015,20:518-526.	57.	 Winston	A,	Amin	J,	Mallon	P,	Marriott	D,	Carr	A,	Cooper	DA,	et	al.	Minor	changes	in	calculated	creatinine	clearance	and	anion-gap	are	associated	with	tenofovir	disoproxil	fumarate-containing	highly	active	antiretroviral	therapy.	HIV	Med	2006,7:105-111.	58.	 Kidney	Disease:	Improving	Global	Outcomes	(KDIGO)	Acute	Kidney	Injury	Work	Group.	KDIGO	Clinical	Practice	Guideline	for	Acute	Kidney	Injury.	
Kidney	Inter.,	Suppl.	2012,2:1-138.	
	 56	
59.	 Siew	ED,	Ikizler	TA,	Matheny	ME,	Shi	Y,	Schildcrout	JS,	Danciu	I,	et	al.	Estimating	baseline	kidney	function	in	hospitalized	patients	with	impaired	kidney	function.	Clin	J	Am	Soc	Nephrol	2012,7:712-719.	60.	 Wald	R.	Predicting	baseline	creatinine	in	hospitalized	patients.	Clin	J	Am	
Soc	Nephrol	2012,7:697-699.	61.	 Okusa	MD,	Davenport	A.	Reading	between	the	(guide)lines--the	KDIGO	practice	guideline	on	acute	kidney	injury	in	the	individual	patient.	Kidney	
Int	2014,85:39-48.	62.	 Gaiao	S,	Cruz	DN.	Baseline	creatinine	to	define	acute	kidney	injury:	is	there	any	consensus?	Nephrol	Dial	Transplant	2010,25:3812-3814.	63.	 Bellomo	R,	Ronco	C,	Kellum	JA,	Mehta	RL,	Palevsky	P.	Acute	renal	failure	-	definition,	outcome	measures,	animal	models,	fluid	therapy	and	information	technology	needs:	the	Second	International	Consensus	Conference	of	the	Acute	Dialysis	Quality	Initiative	(ADQI)	Group.	Crit	Care	2004,8:R204-212.	64.	 Kashani	K,	Kellum	JA.	Novel	biomarkers	indicating	repair	or	progression	after	acute	kidney	injury.	Curr	Opin	Nephrol	Hypertens	2015,24:21-27.	65.	 Jafari	A,	Khalili	H,	Dashti-Khavidaki	S.	Tenofovir-induced	nephrotoxicity:	incidence,	mechanism,	risk	factors,	prognosis	and	proposed	agents	for	prevention.	Eur	J	Clin	Pharmacol	2014,70:1029-1040.	66.	 Shisana	O,	Rehle	T,	Simbayi	LC,	K.	Z,	Jooste	S,	Zungu	N,	et	al.	South	African	National	HIV	Prevalence,	Incidence	and	Behaviour	Survery,	2012.	Cape	
Town:	HSRC	Press	2014:1	-	198.	67.	 Hoffmann	CJ,	Hoffmann	JD,	Kensler	C,	van	der	Watt	M,	Omar	T,	Chaisson	RE,	et	al.	Tuberculosis	and	hepatic	steatosis	are	prevalent	liver	pathology	
	 57	
findings	among	HIV-infected	patients	in	South	Africa.	PLoS	One	2015,10:e0117813.	68.	 Parkhie	SM,	Fine	DM,	Lucas	GM,	Atta	MG.	Characteristics	of	patients	with	HIV	and	biopsy-proven	acute	interstitial	nephritis.	Clin	J	Am	Soc	Nephrol	2010,5:798-804.	69.	 Zaidan	M,	Lescure	FX,	Brocheriou	I,	Dettwiler	S,	Guiard-Schmid	JB,	Pacanowski	J,	et	al.	Tubulointerstitial	nephropathies	in	HIV-infected	patients	over	the	past	15	years:	a	clinico-pathological	study.	Clin	J	Am	Soc	
Nephrol	2013,8:930-938.	70.	 Leone	S,	Nicastri	E,	Giglio	S,	Narciso	P,	Ippolito	G,	Acone	N.	Immune	reconstitution	inflammatory	syndrome	associated	with	Mycobacterium	tuberculosis	infection:	a	systematic	review.	Int	J	Infect	Dis	2010,14:e283-291.	71.	 Siew	ED,	Peterson	JF,	Eden	SK,	Moons	KG,	Ikizler	TA,	Matheny	ME.	Use	of	multiple	imputation	method	to	improve	estimation	of	missing	baseline	serum	creatinine	in	acute	kidney	injury	research.	Clin	J	Am	Soc	Nephrol	2013,8:10-18.		
 
 
 
 
 
 
 
	 58	
Chapter 3: Appendix 
i. Data collection sheet 
BASELINE DATA 
PID  
DATE OF RECRUITMENT 
 DATE OF BIRTH  
AGE  
GENDER – Male/Female 
ETHNICITY 
Black 
Coloured 
White 
Indian 
Other 
Date of Admission 
Date of Discharge 
FOR CURRENT AND PREVIOUS ARV STATUS 
Is the patient on ARVs now or has the patient ever taken ARVs before this admission? 
IF YES -> PLEASE GIVE INFORMATION OF ALL ARVS PATIENT HAS 
TAKEN BOTH NOW AND PREVIOUSLY 
CODING 
FDC – 1, TDF – 2, D4T – 3, AZT – 4, ABC – 5 , DDI – 6, 3TC – 7, EFV – 8,  
NVP – 9, ALLUVIA – 10 
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CODE DATE 
STARTED 
DATE 
STOPPED 
REASON FOR STOPPING 
 DD/MM/YYYY DD/MM/YYY
Y 
SIDE 
EFFECT 
DRUG 
RESISTANCE 
DEFAULT 
      
      
      
      
      
      
 
TB AND OTHER OPPORTUNISTIC INFECTIONS 
1. Has the patient been treated for TB before this admission?  - Y/N 
IF NO -> STOP 
IF YES - > DATE OF TREATMENT STARTED 
• DATE 1 – MM/YYYY 
• DATE 2 – MM/YYYY 
2. Is the patient on  TB treatment that was started before this admission? – Y/N 
IF NO -> STOP 
IF YES –  a) What was the date of treatment started?  
• Date 
       b) Were was the TB Diagnosed? 
           CHOOSE ONE: 
• Local Clinic 
• Hospital 
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      c) How was the TB Diagnosed? 
• Empiric 
• Sonar 
• Sputum 
• Chest X – Ray 
• Other 
3. Is the patient being tested for TB on this admission? – Y/N 
IF NO -> STOP 
IF YES Were the following tests done? 
 – a) Sputum GXP Done? – Y/N 
  Barcode 
  GXP Result – Pos/Neg 
  If Positive – Rif Sens / Rif Resis 
- b) LPA Done? Y/N 
-  Barcode 
-  LPA Result – Pos/Neg 
-  If Positive – Rif Sens/Rif Resis 
-  If Positive – INH Sens/INH Resis 
- c) TB Culture Done? 
-  Barcode 
-  TB Culture Result – MTB Pos / MTB Neg 
4. Does the patient currently have cryptococcal meningitis? – Y/N 
• IF YES – Date of diagnosis – DD/MM/YYYY 
5. Has the Patient previously had cryptococcal meningitis? – Y/N 
• IF YES – Date of diagnosis – MM/YYYY 
	 61	
CO – MORBIDITIES 
Does the patient have any co-morbidities? – YES/NO 
YES – Select from List 
• Hypertension 
• Diabetes 
• Asthma 
• Epilepsy 
• Chronic Kidney Disease 
• Cardiac Disease 
• Other 
For Each Co – Morbidity Selected as Yes 
- What is the duration of the co – morbidity? 
- Wks / mths/ yrs 
LIST ANY KNOWN MEDICATIONS TAKEN WITHIN ONE MONTH PRIOR TO 
ADMISSION 
Medication 1 – Name 
ETC 
GIT HISTORY 
1. Is the patient vomiting? – Y/N 
YES – For How long is the patient vomiting - DURATION IN DAYS 
2. Does the patient have diarrhea? – Y/N 
YES – For How Long does the patient have diarrhea – DURATION IN DAYS 
• How many Stools per day?  - patient to give number 
• Is it watery? Is there Blood? 
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• SELECT 
o Watery 
o Blood 
o Both 
• Has a stool MC/S been sent 
• YES – Barcode 
IMPORTANT EXPOSURES 
1. Has the patient taken traditional medications in the last two months? – Y/N 
IF YES – What is the name of the traditional medication? 
2. Has the patient worked in a mine? – YES/NO 
YES – What type of mining (gold, coal, uranium)? 
For how long did the patient work in the mine? 
3. Does the patient use Non –Steroidal Inflammatories? – Y/N 
Eg: Aspirin, Disprin, Grandpa, Brufen, Feldene, Myprodol  
IF YES – HAS THE PATIENT USED NSAIDS IN THE LAST MONTH BEFORE 
ADMISSION – Y/N 
QUANTIFY – More Than 5 Doses per Week OR Less Than 5 Doses per Week 
OUTCOMES 
1. How was the Patient treated? 
SELECT 
• Ward – Fluids 
• Dialysis 
2. What was the patient outcome? 
SELECT 
• Recovered = UE Normal/Improving on Discharge 
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• Dialysis 
• Death 
3. Has the patient been started on TB treatment on this admission? – Y/N 
IF YES – What is the reason for TB Treatment? 
SELECT 
1) Empiric 
2) Sonar 
3) Sputum – Barcode 
4) Chest X – Ray 
5) Other 
4. Discharge diagnosis 
List Discharge diagnosis from Discharge Summary 
Particular Attention to Cause of Renal Failure to be stated 
5. Discharge ARVs 
CODING 
FDC – 1, TDF – 2, D4T – 3, AZT – 4, ABC – 5 , DDI – 6, 3TC – 7, EFV – 8,  
NVP – 9, ALLUVIA – 10 
CODE DATE 
STARTED 
 DD/MM/YYYY 
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LABORATORY AND RADIOLOGICAL INVESTIGATIONS 
  ADMISSION DATE BARCODE DISCHARGE DATE BARCODE 
HIV BLOODS             
CD4 – cells/mm3             
VIRAL LOAD (WITHIN 
THE LAST 3 MONTHS) – 
copies/ml             
RENAL IX             
WEIGHT (KG)             
HEIGHT (M)       
NA   
    
  
    
K     
HCO3     
CL     
UREA     
CREATININE     
eGFR     
WCC   
    
      
HB         
PLATLETS         
CRP             
CALCIUM   
    
      
MAGNESIUM         
PHOSPHATE         
ALBUMIN         
FERRITIN             
HEPATITIS B  SAg Pos / Neg           
URINE             
DIPSTICKS GLUCOSE           
BEDSIDE HGT       
UPCR             
U PHOSPHATE 
U AMINO 
ACIDS           
SONAR             
KIDNEYS             
RIGHT KIDNEY SIZE             
LEFT KIDNEY SIZE             
HYDRONEPHROSIS YES NO         
HYPERECHOIEC YES NO         
ABDOMEN             
ASCITES YES NO         
PARAAROTIC 
LYMPHNODES YES NO         
MICROSPLENIC 
ABSCESSES YES NO         
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XRAY 
Is a Chest Xray Done? 
YES 
SELECT ONE OF THE FOLLOWING 
- Cavities 
- Infiltrates 
- Pleural Effusion 
- Pulmonary Oedema 
- Normal 
X – RAY IMAGE UPLOADED 
YES - > Image 
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2 WEEK / 1 MONTH FOLLOW UP – DATA SHEET NUMBER: 
    DATE BARCODE 
WEIGHT (KG)       
NA   
    
K   
HCO3   
CL   
UREA   
CREATININE   
eGFR   
 
TREATMENT   
ARVS 
TDF / AZT / ABC / D4T 
3TC 
EFV / NVP / ALLUVIA 
    
TB TREATMENT   
 
  
OTHER INTERCURRENT ILLNESS 
TREATMENT 
EG: CRYPTO 
HT/DM/EPILEPSY ETC   
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2-MONTH FOLLOW UP – DATA SHEET NUMBER: 
    DATE BARCODE 
WEIGHT (KG)       
        
NA   
    
K   
HCO3   
CL   
UREA   
CREATININE   
eGFR   
 
TREATMENT   
ARVS 
TDF / AZT / ABC / D4T 
3TC 
EFV / NVP / ALLUVIA 
    
TB TREATMENT   
    
OTHER INTERCURRENT ILLNESS 
TREATMENT 
EG: TB, CRYPTO 
HT/DM/EPILEPSY ETC   
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3-MONTH FOLLOW UP – DATA SHEET NUMBER: 
    DATE BARCODE 
WEIGHT (KG)       
NA   
    
K   
HCO3   
CL   
UREA   
CREATININE   
eGFR   
CALCIUM   
    
MAGNESIUM   
PHOSPHATE   
ALBUMIN   
UPCR       
U PHOSPHATE       
 
TREATMENT   
ARVS 
TDF / AZT / ABC / D4T 
3TC 
EFV / NVP / ALLUVIA 
  
TB TREATMENT   
 
  
OTHER INTERCURRENT ILLNESS TREATMENT 
EG: TB, CRYPTO 
HT/DM/EPILEPSY ETC   
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Acute Kidney Injury, Risk Factors, and Prognosis
in Hospitalized HIV-Infected Adults in South Africa,
Compared by Tenofovir Exposure
Faheem Seedat,1 Neil Martinson,2,3 Katlego Motlhaoleng,2 Pattamukkil Abraham,2 Dalu Mancama,4
Saraladevi Naicker,1 and Ebrahim Variava1
Abstract
There are limited data describing acute kidney injury (AKI) in HIV-infected adult patients in resource-limited settings
where tenofovir disoproxil fumarate (TDF), which is potentially nephrotoxic, is increasingly prescribed. We describe
risk factors for and prognosis of AKI in HIV-infected individuals, stratified by those receiving and those naive to TDF.
A prospective case cohort study of hospitalizedHIV-infected adults with AKI stratified by TDF exposure. Adults (‡18
years) were recruited: clinical and biochemical data were collected at admission; their renal recovery, discharge, or
mortality was ascertained as an in-patient and, subsequently, to a scheduled 3-month follow-up. Among this pre-
dominantly female (61%), almost exclusively black African cohort of 175 patients with AKI, 93 (53%) were TDF
exposed; median age was 41 years (interquartile range 35–50). Median CD4 count and viral load and creatinine at
baseline were 116 cells/mm3 and 110,159 copies/ml, respectively. A greater proportion of the TDF group had severe
AKI on admission (61% vs. 43%, p= .014); however, both groups had similar rates of newly diagnosed tuberculosis
(TB; 52%) and nonsteroidal anti-inflammatory drug (NSAID; 32%) use. Intravenous fluid was the therapeutic
mainstay; only sevenwere dialyzed. Dischargemedian serum creatinine (SCr) was higher in the TDF group ( p= .032)
and fewer in the TDF group recovered renal function after 3 months (p= .043). Three-month mortality was 27% in
both groups, but 55% of deaths occurred in hospital. Those that died had a higher SCr and more severe AKI than
survivors; TB was diagnosed in 33 (70%) of those who died. AKI was more severe and renal recovery slower in the
TDF group; comorbidities, risk factors, and prognosis were similar regardless of TDF exposure. Because TB is linked
to highermortality, TB coinfection in HIV-infected patients with AKIwarrantsmore intensivemonitoring. In all those
with poor renal recovery, our data suggest that a lower threshold for dialysis is needed.
Keywords: acute kidney injury, renal insufficiency, HIV, tenofovir, South Africa, mortality
Background
Acute kidney injury (AKI) is a major cause of mor-bidity and mortality in HIV-infected individuals.1,2
Mortality in hospitalized HIV-infected adults is higher
in those with AKI, while in adults living with HIV the
risk of kidney disease is almost fourfold that of HIV-
uninfected adults.3,4 Antiretroviral therapy (ART) miti-
gates this risk.1
Numerous studies from developed settings have reported
AKI in HIV-infected individuals, suggesting that the etiology
of AKI is multifactorial. Moreover, both HIV and ART are
directly nephrotoxic.1,3–6 Prerenal AKI from renal hypo-
perfusion (commonly from gastroenteritis), sepsis-induced
acute tubular necrosis (ATN), and concomitant nephrotoxic
drug use are common causes of AKI in HIV-infected
adults.2,5,7,8Well-described risk factors for AKI apply to both
HIV-seronegative and seropositive individuals.1,3–7,9,10
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However, specific risk factors in HIV-seropositive individ-
uals include: male sex; advanced immunosuppression; long-
term ART use; and preexisting renal disease.3–7,9–11
InOctober 2001, the Food andDrugAdministration approved
tenofovir disoproxil fumarate (TDF) as the first nucleotide
reverse-transcriptase inhibitor (NRTI) for the treatment of
HIV.12 SinceApril 2010, TDF has been themainstay of first line
ART in SouthAfrica: massively increasing the number of South
Africans receiving TDF.13 Although not initially reported in the
early clinical trials, subsequent case reports, case series, and ob-
servational studies reported TDF-associated nephrotoxicity and,
in 2010, a systematic review and meta-analysis reported a sig-
nificant decline in renal function associated with TDF use.14–19
The mechanism of action appears to be the accumulation
of TDF in proximal tubular cells (due primarily to genetic
polymorphisms encoding defective transmembrane drug
transporters), with resultant mitochondrial toxicity and sub-
sequent renal injury, clinically presenting as the Fanconi
syndrome or ATN with AKI.16,20–22 The reported prevalence
of TDF-related nephrotoxicity is 2.4% occurring at 6–9
months following TDF initiation, although South African
studies suggest an earlier onset.11,17–19,22–25
We report the presentation, severity, and risk factors for
AKI in HIV-positive South African patients and assess the
response to treatment and short-term outcomes. Furthermore,
to assess the role of TDF in HIV-positive patients with AKI,
analysis was stratified by TDF exposure.
Materials and Methods
This prospective case cohort study recruited patients from
the Klerksdorp/Tshepong Hospital Complex, a secondary
level public hospital in South Africa’s North West province,
from October 2014 to June 2015. We enrolled HIV-infected
patients admitted to the adult medicine wards with AKI and
compared those exposed to TDF to those who had not re-
ceived TDF and followed them up after discharge. Eligible
patients were: hospitalized, HIV-infected adults, and ‡18
years of age with a diagnosis of AKI. We excluded patients
with prior or preexisting kidney disease (either self-reported
or as indicated by medical records or laboratory results).
Those who appeared unwilling or incapable of attending
follow-up and those whose clinical records were inadequate
to assess renal function or HIV treatments before the study
were also excluded. The University ofWitwatersrand Human
Research Ethics Committee approved this study.
Study definitions and measures
Patients were categorized as TDF exposed if they were on
TDF-based ART at the time of admission or had defaulted
TDF for <1 week before admission. The TDF unexposed
group included individuals who: were ART naive, were
taking non-TDF-based ART, had defaulted non-TDF based
ART for any duration, and those who had defaulted TDF
based ART for at least 8 weeks before the onset of AKI.
In all study patients, AKI was diagnosed and staged ac-
cording to the Kidney Disease Improving Global Outcomes
(KDIGO) 2012 Clinical Practice AKI Guideline.26 Baseline
serum creatinine (SCr) before AKI was determined either by
a SCr taken before, but within the preceding year of admis-
sion, or the lowest normal SCr at discharge or on follow-
up.27,28 If no baseline SCr was available, an estimated
baseline SCr was calculated based on a Modification of Diet
in Renal Disease (MDRD) equation estimated glomerular
filtration rate (eGFR) of 75ml/min per 1.73m2.26,29,30
Renal recovery was defined as a decreasing SCr over time
and no need for continuing renal replacement therapy (RRT)
and was categorized as complete (SCr recovery below 1.5
times the baseline) or partial (SCr recovery above 1.5 times the
baseline).31,32 New admissions to the acute care adult medical
ward were screened for eligibility on weekdays. If eligible,
written informed consent was obtained and a structured interview
administered assessing: ART use, previous tuberculosis (TB)
history, comorbidities, concomitant gastrointestinal symptoms,
drug history, and other important exposures; necessary blood and
urine samples were taken, results of radiological investigations
recorded, and relevant information from clinical records noted.
On discharge, a summary of the clinical course of the
patient was abstracted from the medical records. Patients
were then actively followed up at a visit scheduled 3 months
after discharge.
Statistical analyses
Patient demographic and clinical characteristics are re-
ported as medians and interquartile ranges (IQRs) for con-
tinuous variables and proportions with 95% confidence
intervals (95% CIs) for categorical variables. These were
compared between groups using the Mann–Whitney,
Kruskal–Wallis, and Chi-square tests as appropriate. Uni-
variable logistical regression was used to control for TDF use
and the presence of TB coinfection. Multivariable regression
was not performed due to the small sample size and some
missing data. All statistical analyses were performed using
STATISTICA version 12 (StatSoft).
Results
From 1 October 2014 to 30 June 2015, 199 HIV-infected
patients with presumed AKI were enrolled in this study; 24
were subsequently excluded as they either had prior kidney
disease (16) or had defaulted TDF based ART for <8 weeks
(8). Of the remaining 175, their median age was 41 years (IQR
35–50); 61% were women; virtually all (99%) were black Af-
ricans; and their median body mass index was 21 kg/m2 (IQR
19–24) on admission (Table 1). Ninety-three (53%) were
TDF exposed for a median treatment duration of 30 weeks
(IQR 8–61) of whom 27 (29%) had prior ART exposure
before switching to a TDF containing regimen. The majority
of the TDF group (94%) received a concomitant non-NRTI
(NNRTI) and 6% a protease inhibitor. Thirty-one patients in
the non-TDF group were receiving ART for a median dura-
tion of 306 weeks (IQR 88–729); 62% of the non-TDF group
was ART-naive on admission.
AKI severity and measures of kidney disease
Half (53%) of all participants had severe AKI, most were in
the TDF group (62%; n= 57), whereas mild AKI was pre-
dominant in the non-TDF group (62%; n= 23) (Fig. 1). The
TDF group had: a higher median admission SCr (282lmol/l;
IQR 172–542 vs. 189lmol/l; IQR 146–343; p= .007); higher
median urine protein creatinine ratio (0.212 g/mmol creat; IQR
0.111–0.316 vs. 0.128 g/mmol creat; IQR 0.087–0.212;
p= .003); and a lower median eGFR (CKD-EPI) (14.2ml/min;
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IQR 4.3–28 vs. 25.6ml/min; IQR 10.4–39.5; p= .002) and was
more acidotic (serum bicarbonate 14lmol/l; IQR 10–18 vs.
16lmol/l; IQR13–19; p= .047). The odds ratio (OR) for severe
AKI in the TDF group was 1.2 (1.02–1.40; 95% CI; p= .013)
compared to those who were not exposed to TDF (Table 2).
Markers of proximal tubular dysfunction (urine phosphaturia
and glycosuria, serum hypophosphatemia and hypokalemia)
were not markedly deranged in either group. Laboratory re-
sults suggestive of interstitial nephritis were present in many,
with high rates of leukocyturia (n= 47; 32%) and hematuria
(n= 81; 55%) in sterile urine specimens, but there was no
significant difference in the two groups—only 29 (17%) of all
patients had a culture positive urinary tract infection.
Comorbidities and risk factors for AKI
Half of both groups (50%TDF vs. 55% non-TDF; p = .474)
were newly diagnosed with TB, and overall a prior history of
TB treatment was reported by 39%. Gastrointestinal symp-
toms, vomiting, and diarrhea were reported more frequently
in the TDF group (39% vs. 21%; p = .008) and twice as
many patients in the TDF group reported chronic diarrhea
Table 1. Baseline Demographic Characteristics, Comorbidities, Risk Factors, and Laboratory
Characteristics in Acute Kidney Injury Patients at Admission Stratified
by Tenofovir Disoproxil Fumarate Exposure (n= 175)
TDF Non-TDF p
93 (53) 82 (47)
Demographics
Age (years), median (IQR) 42 (35–53) 40 (35–49) .260
Female, n (%) 62 (67) 45 (55) .110
Black, n (%) 91 (98) 83 (100) .182
Serum electrolytes
Potassium (mmol/l), median (IQR) 4.1 (3.3–5.1) 4.3 (3.5–5.2) .348
Bicarbonate (lmol/l), median (IQR) 14 (10–18) 16 (13–19) .047
Phosphate (mmol/l), median (IQR) 1.2 (0.8–1.7) 1.3 (0.9–1.6) .496
Renal parameters
Admission creatinine (lmol/l), median (IQR) 282 (172–542) 189 (146–343) .007
Admission eGFR-CKD-EPI (ml/min per 1.73m2),
median (IQR)
14.2 (4.3–28) 25.6 (10.4–39.5) .002
Baseline creatinine (lmol/l), median (IQR) 77 (65–88) 77 (62–92) .920
Urine protein:creatinine ratio (g/mmol creat),
median (IQR)
0.212 (0.111–0.316) 0.128 (0.087–0.212) .003
Normoglycemic glycosuria, n (%) 7 (11) 6 (10) .863
Hyperechoic, n (%) 71 (91) 48 (84) .226
Right kidney size (cm), median (IQR) 11.25 (10.3–12.2) 11 (10.2–11.8) .347
Left kidney size (cm), median (IQR) 11.4 (10.7–12.3) 11 (10.4–11.8) .135
Comorbidities
Hypertension, n (%) 22 (24) 16 (20) .507
Diabetes, n (%) 8 (9) 3 (4) .179
Hepatitis B positive, n (%) 11 (12) 9 (11) .86
Risk factors
TB, n (%)
Completed TB treatment before admission 35 (38) 34 (41) .605
Newly diagnosed TB 46 (50) 45 (55) .474
Sputum or culture proven TB 22 (48) 22 (49) .919
Pneumonia, n (%) 9 (10) 12 (17) .148
Sepsis, n (%) 4 (4) 7 (9) .249
Vomiting, n (%) 32 (34) 14 (17) .009
Diarrhea, n (%) 36 (39) 17 (21) .008
NSAID use, n (%) 26 (28) 30 (37) .784
HIV-related and infective parameters
CD4 count (cells/mm3), median (IQR) 147 (57–304) 87 (41–210) .067
HIV viral load (copies/ml)
Virally suppressed (LDL or <1,000), n (%) 56 (60) 14 (17) <.001
Median HIV viral load in those >1,000,
median (IQR)
39,456 (4,537–326,300) 414,365 (110,159–1,521,015) <.001
Hemoglobin (g/dl), median (IQR) 9.6 (7.8–11.3) 9.8 (7.4–12) .622
C-reactive protein (mg/l), median (IQR) 127 (39–189) 89 (37–180) .386
Albumin (g/l), median (IQR) 20 (16–24) 18 (15–23) .122
Ferritin (lg/l), median (IQR) 490 (205–1,171) 750 (366–1,415) .047
eGFR, estimated glomerular filtration rate; IQR, interquartile range; NSAID, nonsteroidal anti-inflammatory drug; TB, tuberculosis;
TDF, tenofovir disoproxil fumarate.
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( p = .522). Furthermore, in patients with severe AKI, the OR
of vomiting [OR–1.14 (1.00–1.30; 95% CI; p = .046)] and
diarrhea [OR–1.20 (1.05–1.30; 95% CI; p = .007)] was sig-
nificantly increased (Table 2).
Noninfectious comorbidities: hypertension (22%) and dia-
betes (6%) were reported at similar rates in both groups. Re-
ceipt of traditional medication was infrequently self-reported,
but high rates of nonsteroidal anti-inflammatory drug (NSAID)
use, within the month before admission, were reported by both
groups. A greater number of TDF-exposed patients were vi-
rally suppressed than ART-treated patients from the non-TDF
group ( p= .017); and in those not suppressed, the median viral
load was lower in the TDF group ( p= .002).
Treatment and outcomes
The overwhelming majority of patients received intra-
venous fluid therapy (96%) and only seven received RRT.
In those who received RRT, the admission SCr was sig-
nificantly higher than those treated with intravenous fluid
therapy: median SCr 553 lmol/l; IQR 471–623 vs. 216 lmol/
l; IQR 156–438, p = .021; furthermore, all seven patients
presented with severe AKI, p= .037. However, there were no
statistical differences in the two groups in: TDF exposure and
risk factors for AKI.
Eighty-five percent of all patients recovered sufficiently to be
discharged from hospital. Even though the median length of
hospital stay was the same in both groups (9 days), the TDF
group had delayed renal recovery with higher SCr on discharge:
median SCr 120lmol/l; IQR 87–240 vs. 97lmol/l; IQR 75–
137; p= .032 (Fig. 2). Moreover, a smaller proportion of TDF
exposed patients had complete renal recovery at the 3-month
postdischarge follow-up visit (61%vs. 78%; p= .043) (Table 3).
Although TDFwas stopped on admission in all patients, at 3-
month follow-up, 55 patients (31%) had been restarted on full
dose TDF based ART without apparent adverse effects, 38
(22%) of whom had been TDF exposed on admission. Only one
patient who was reinitiated on TDF was subsequently changed
to non-TDF based ART. No significant difference in renal re-
covery ( p= .114) or mortality ( p= .105) at 3-month follow-up
was found in those reinitiated on TDF compared to those where
non-TDF based ART was used following discharge.
Furthermore, among the TDF exposed group, no signifi-
cant difference was noted in mortality or renal recovery at
discharge or at 3-month follow-up when stratifying for du-
ration of TDF use (Table 3).
In those who died during their hospital stay, no difference
was noted in either SCr values measured before death or in
renal recovery when comparing the TDF and non-TDF
groups (Table 3). Fifty-five percent of deaths occurred in
FIG. 1. Severity of acute kidney
injuryonadmission stratifiedbyTDF
exposure. TDF, tenofovir disoproxil
fumarate.
Table 2. Univariable Analysis to Determine Risk of Severe Acute Kidney Injury
and Mortality at 3-Month Follow-Up
Severe AKI Mortality after 3-month follow-up
OR (95% CI) p OR (95% CI) p
TDF exposure 1.20 (1.02–1.40) .013 1.00 (0.86–1.14) .993
HIV viral load suppressed 1.10 (0.95–1.27) .196 1.07 (0.90–1.26) .763
TB coinfection 1.05 (0.90–1.22) .516 1.21 (1.06–1.38) .003
Vomiting 1.14 (1.00–1.30) .046 1.14 (0.99–1.30) .073
Diarrhea 1.20 (1.05–1.30) .007 1.12 (0.96–1.30) .164
NSAID use 1.06 (0.92–1.22) .409 0.97 (0.83–1.14) .706
Severe AKI N/A N/A 1.10 (0.97–1.26) .144
95% CI, 95% confidence interval; AKI, acute kidney injury; OR, odds ratio.
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hospital and they had a higher median SCr before death
compared to the median SCr at discharge in survivors
( p < .001). Furthermore, most patients who died in hospital
had severe AKI immediately before death ( p < .001).
Sixteen (9.1%) patients were lost to follow-up after dis-
charge. In those who died following discharge, similar
mortality rates were found in both groups ( p = .383). When
assessing overall outcome, from admission to 3-month
follow-up, the mortality rate in both groups was 27%, but the
duration from admission to death and discharge to death was
significantly shorter in the TDF group (Table 3). Seventy
percent (n= 33) of those who died were newly diagnosed with
TB compared to 42% of survivors ( p = .001), and the OR of
mortality at 3-month follow-up in those newly diagnosed
with TB was 1.21 (1.06–1.38; 95% CI, p = .003) compared to
those without TB (Table 2). Similarly, elevated C-reactive
protein and anemia were more frequently found in patients
who died in this cohort.
Discussion
This prospective cohort suggests that HIV-infected pa-
tients with AKI who also received TDF-based ART had more
severe AKI and a higher presenting median SCr compared to
those on non-TDF-based ART. Moreover, the renal recovery
was slower in those taking TDF. In-hospital outcomes, du-
ration of admission, and overall mortality, however, were
similar in both TDF exposed and unexposed groups. AKI in
HIV-infected individuals has a poor prognosis, as more than a
quarter of the patients in this cohort died.
In our study, TDF exposed HIV-infected patients who
develop AKI have a similar etiology and rate and range of
nephrotoxic risk factors that we measured as those not re-
ceiving TDF. However, our data suggest that TDF has an
added nephrotoxic effect in patients with AKI causing: a
more rapid worsening of renal function; a higher proportion
with proteinuria and acidosis; and delayed renal recovery.
The data on TDF use and AKI in Southern Africa are
limited; previous studies in ambulatory patients report a
frequency of TDF-associated nephrotoxicity of just less than
3% and risk factors for nephrotoxicity with TDF use include:
preexisting renal dysfunction, anemia, and immunosuppres-
sion.24,25 This study is the first we are aware of that reports
AKI, stratified by TDF exposure, in hospitalized HIV-
positive patients in South Africa, and is particularly relevant
due to the massive increase in prescriptions of TDF as part of
first line ART in the country.33
RRT use was limited in this cohort, despite increasing SCr
in over a third of those who died during admission and despite
no formal restrictions or eligibility criteria for the initiation of
RRT in this setting. We postulate that RRT may have pre-
vented some deaths. Moreover, the substantial mortality fol-
lowing discharge from hospital suggests that more intensive
monitoring and follow-up after discharge from hospital are
necessary in all patients with AKI. Further studies are required
to assess the likely causes of and contributors to death and to
better identify potential interventions to prevent mortality.
Consistent with our findings, international studies have
reported the duration of TDF exposure before onset of decline
in renal function to be 6–9 months,18,23 although studies of
ambulatory patients in South Africa report a shorter median
time to nephrotoxicity (3.6 months).24,25
Current recommendations suggest that TDF dose adjust-
ment is necessary in those with renal injury while on TDF.34
Although published literature reportsmale gender and lower
body weight as risk factors associated with AKI,18,19,23,25 the
high proportion of women with AKI that we report is likely
due to higher seroprevalence of HIV among South African
women and national policy to initiate ART in all HIV-positive
pregnant women irrespective of CD4 count.33,35
The apparent role of TB, which was frequently diagnosed
in this cohort, in contributing to both morbidity and mortality
following discharge is substantial. The association between
AKI and TB is described in a retrospective cohort from Jo-
hannesburg, in which 26% of HIV-positive patients with AKI
were diagnosed with TB, almost half of what we report.8
However, over half of the cases of TB we report were not
laboratory confirmed.36
Fifty-three percent of our cohort had laboratory findings
suggestive of interstitial nephritis, which could be at least
FIG. 2. Comparison of median
SCr values stratified by TDF ex-
posure at various time intervals:
baseline before admission; on ad-
mission; on discharge; in survivors
to discharge; and in deaths during
hospital stay. SCr, serum creati-
nine.
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partially attributed to TB and/or NSAID use, although this
finding is limited by the absence of renal biopsies in this
cohort.37,38 While the immune reconstitution inflammatory
syndrome (IRIS) is a known cause of an interstitial nephritis,
the duration of ART exposure in the majority of our patients
was for a longer period than that associated with the onset of
IRIS; moreover, some patients were ART naive.38,39
This study has several limitations. We restricted our
sample to patients admitted to a single regional hospital in
South Africa and we are unable to report the overall rate of
AKI in TDF and other ART recipients. Tubular dysfunction
using urine beta-2 microglobulin and fractional excretion of
phosphate was not measured, and in some patients, not every
study parameter was measured, but all had sufficient mea-
sured data to be eligible for inclusion.
Baseline SCr values were not available in all patients and
missing baseline values were inferred using the MDRD for-
mula (calculated using an eGFR of 75ml/min/1.73m2); this
may have biased the classification of AKI severity in both the
TDF, but particularly in the non-TDF group where baseline
SCr levels were less readily available as ART-naive patients
infrequently had a measured SCr before admission or on
follow-up.28,40
Furthermore, no renal biopsies were performed in this
cohort, particularly in those with partial renal recovery; how-
ever, in most instances, the etiology of AKI was clinically
evident. Finally, the small sample size of the study andmissing
data values limited the regression analysis of this cohort.
Comparison of the two groups suggests that risks factors,
etiology, and mortality of AKI in HIV-infected in-patients,
irrespective of TDF use, are similar, but that coexisting TDF
use appears to result in more severe and longer lasting AKI.
Our findings suggest that a lower threshold for RRT may be
needed in those with limited or no SCr recovery and intensive
follow-up after discharge from hospital may reduce mortality
in all HIV-infected AKI patients, and especially in those with
concomitant TB.
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